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Abstract 
Due to its long history of industrial applications, extensively studied biology 
and rapid growth rates, Escherichia coli is an important cell factory for 
metabolic engineering and an increasingly popular chassis organism for 
synthetic biology. Serine integrases, which function naturally to incorporate 
bacteriophage DNA into the host genome, represent a powerful and flexible 
tool for the genomic integration of heterologous genes or pathways into host 
organisms. 
 In the system described here, serine integrase enzymes are used to 
recombine two pairs of non-identical attachment sites, located on a 
chromosomally-integrated “landing pad” (LP) and an introduced “donor 
cassette”, resulting in cassette exchange of a transgene into a known locus on 
the E. coli genome. In this work, a landing pad was designed for φC31 
integrase, consisting of two φC31 attB sites, both with differing central 
dinucleotide pairs, in a head-to-head orientation flanking an erythromycin 
resistance marker gene. This φC31 LP was inserted into the E. coli genome, 
replacing the non-essential pepA gene, by recombineering. Cassette exchange 
experiments were then performed, in which a temperature-sensitive plasmid 
carrying a donor cassette consisting of corresponding attP sites to the φC31 LP 
attB sites flanking an antibiotic resistance marker was transformed under the 
inducible expression of φC31 integrase. 
 Serine integrases recombine their target sites in a highly unidirectional 
reaction. The reverse excision reaction, between integration product sites 
attL and attR, can only proceed with the addition of the integrase-associated 
recombinational directionality factor (RDF). Using in vitro recombination 
assays, TG1 integrase was shown to have very highly controlled directionality.  
Addition of the TG1 RDF gp25 strongly activates attL-attR recombination, 
taking recombination activity from a background level of 9% to 72% 
recombination of the substrate. TG1 gp25 also strongly inhibits attP-attB 
recombination, decreasing recombination from 77% to 8%. This demonstrates 
its potential as a highly controllable recombinase for synthetic biology. This 
work also investigated cross-reactivity of integrases and their non-cognate 
RDFs, showing that the TG1 RDF gp25 is able to activate φC31 integrase attL-
attR recombination, however does not similarly inhibit φC31 attP-attB. 
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Abbreviations 
ApR   Ampicillin resistance 
att   Integrase attachment site 
bp   Base pair 
CmR   Chloramphenicol resistance 
CRISPR  Clustered regularly interspaced short palindromic  
   repeats 
ddH2O  Double distilled water 
DICE   Dual integrase cassette exchange 
DNA   Deoxyribonucleic acid 
EDTA   Ethylenediaminetetraacetic acid (disodium salt) 
EmR   Erythromycin resistance 
FLP   Flippase 
GalK   Galactokinase gene 
GFP   Green fluorescent protein 
KnR   Kanamycin resistance 
LB   Lysogeny broth (media) 
LP   Landing pad 
PCR   Polymerase chain reaction 
RDF   Recombinase directionality factor 
RMCE   Recombinase mediated cassette exchange 
SD   Synthetic defined (yeast media) 
SDS   Sodium dodecyl sulphate 
SIRA   Serine integrase recombinational assembly 
ssDNA  Single stranded DNA 
TAE   Tris acetate EDTA (electrophoresis buffer) 
Tris   Tris(hydroxymethyl)aminimethane 
TS   Temperature-sensitive 
YKO   Yeast knockout 
YPD   Yeast extract, peptone, dextrose (media) 
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1.  Chapter 1: Introduction 
1.1  Escherichia coli as a microbial cell factory 
Escherichia coli has a long and successful history as a microbial cell factory 
for expressing commercially-relevant proteins on an industrial scale. Even 
before the advent of recombinant DNA technologies it was one of the first 
microorganisms in which a protein was produced by over-expression, with the 
cellular yield of lactose repressor increased through selection and phage-
mediated expression of an high-expression lacI mutant (Muller-Hill et al., 
1968). After this, the emergence of recombinant DNA techniques such as the 
use of restriction enzymes and in vitro DNA recombination introduced the 
ability to express non-native, heterologous genes in E. coli cells. The first 
biotechnological drugs produced using these techniques included included 
insulin, growth hormone and interferons. Between 1982 and 2013, there have 
been 23 drugs produced in E. coli have been approved for use as 
pharmaceuticals (Baeshen et al., 2015). In fact, 30% of the approved 
therapeutic proteins being produced today use E. coli as an expression host. 
As a highly capable host for producing stably folded, globular proteins from 
both prokaryotic and eukaryotic organisms, there are many advantages to 
choosing E. coli for expressing recombinant proteins. It has an unrivalled 
growth rate among industrially-relevant microorganisms, with a doubling time 
of around 20 minutes, meaning that it only takes a few hours for a culture to 
reach stationary phase (Sezonov et al., 2007) with an upper potential cell 
density of around 1 x 1013 cells per mL (Shiloach & Fass, 2005). On top of this, 
E. coli cells can also achieve very high protein synthesis rates (Sahdev et al., 
2008), in some cases reaching expression levels as high as 30% of the total 
cellular protein (Baeshen et al., 2015). E. coli culture media is also 
inexpensive and can be made using easily available ingredients, making mass 
bioculture relatively cheap for industrial purposes.  
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When designing a strategy for recombinant protein production, there are 
many strains of E. coli  available to choose from, with each tailored for a 
specific function or production requirement, as well as basic expression 
strains that provide a simple background for rapid first expression screening 
(Rosano & Ceccarelli, 2014). In its years of use as an heterologous host, 
extensive libraries of expression vector systems have accumulated, with a 
choice of plasmid parts that allow customised copy number, promoter type, 
selective markers and tags for detection or purification. However, due to the 
precision required for synthetic biology cell engineering systems, many of the 
shortcomings of plasmid-based expression mean that chromosomal integration 
of heterologous genes is preferable. 
1.2  Chromosomal integration of heterologous genes  
1.2.1.  Advantages over plasmid expression 
The traditional method for heterologous gene expression in E. coli and other 
hosts is via plasmid vector expression. This method, for which there are 
numerous libraries of expression vectors, will always be useful for expressing 
target genes on a small scale, for example for purifying a protein of interest 
in the lab. However, as scale of expression and microbial culture increases, 
the plasmid vector expression system begins to become restrictive. Population 
dynamics and growth states tend to have an effect on plasmid copy numbers 
and gene expression levels, making it hard to control expression levels in 
industrial cultures when using plasmid vectors (Lin-Chao & Bremer, 1986). 
Plasmid propagation and maintenance places a burden on cells which may 
already be under significant metabolic strain to express the target protein 
(Birnbaum & Bailey, 1991).  
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In addition, to be maintained in cells many plasmid vectors require constant 
selective pressure, often by antibiotic resistance, which places further strain 
on cells and in larger scale operations can become expensive. Problems with 
plasmid instability can also be encountered, particularly in the case of 
products which may be harmful to the cells such as toxic biopharmaceutical 
and biofuel products. In addition to potential issues during large scale culture, 
assembly and optimisation of plasmid vectors comprising several genes is a 
time-consuming process in which several cloning and screening steps are 
necessary. This can prove a rate-limiting step during metabolic engineering 
and strain development. In recent years there has been a greater focus on the 
integration of heterologous genes into the microbial host genome. This is 
desirable, firstly as it overcomes problems inherent with plasmid vector 
expression, removing the need for constant selective pressure, reducing the 
metabolic burden placed on the cell by plasmid maintenance and avoiding 
problems of instability. Secondly, genomic integration of a target gene can 
allow for a higher level of regulatory control, removing expression 
fluctuations often seen in plasmid expressions. 
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1.2.2.  Currently available methods for chromosomal 
integrations of heterologous DNA 
1.2.2.1.  λ Red recombineering (homologous recombination) 
One of the most common approaches to genomic integration of heterologous 
genes in E. coli is a method of λ phage-assisted homologous recombination, 
termed ‘recombineering’ (Copeland et al., 2001). Homologous recombination 
is a natural cell mechanism performed by E. coli to fix incompletely 
replicated chromosomal DNA during replication and to repair single- and 
double-stranded damage to chromosomal DNA. In E. coli the genes that 
encode this machinery are the Rec genes (Kowalczykowski et al., 1994). The 
process repairs a stretch of DNA by seeking out another copy of the same DNA 
sequence in the cell, identified by sequence homology, unzipping the broken 
DNA and recombining the two DNA molecules to produce two identical in-tact 
double stranded DNA sites. 
In recombineering, the homologous recombination mechanism is hijacked by 
three λ Red proteins: Gam, a nuclease inhibitor, which prevents the E. coli 
nuclease RecBCD from binding and unwinding the linear DNA to be integrated 
(that is introduced to the cell via transformation); Beta, a single strand DNA 
binding protein that aids annealing of homologous sequences on on the target 
site and introduced linear DNA; and Exo, a 5’ to 3’ exonuclease, which creates 
that creates the single strand overhangs to which Beta binds (Sharan et al., 
2009). The recombineering approach requires that the DNA being introduced 
be amplified by PCR with primers that attach homologous sequences (around 
50 bp) at each end. This PCR product is transformed into cells under 
expression of the λ Red elements in order to protect the linear PCR product 
and promote homologous recombination. A diagram of the recombineering 
process is shown in Figure 1.1. 
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Figure 1.1: Overview of the λ Red recombineering method. The gene to be inserted 
into the genome amplified by PCR to be flanked by sequences homologous to the 
site on the genome being targeted. Gam first protects the inserted linear DNA from 
degradation by E. coli nucleases. The λ 5’ to 3’ exonuclease Exo creates 3’ 
overhangs on the linear DNA homology region. Beta then binds to the single 
stranded overhangs and promotes annealing and homologous recombination with 
the genomic target site, resulting in the gene being inserted onto to E. coli genome 
at the predetermined site. Based on Sharan et al., 2009.
1.2.2.2.  Phage recombinase-assisted integration 
The earliest examples of site-specific recombinases being utilised for genomic 
rearrangements in prokaryotes or eukaryotes were the tyrosine recombinase 
Cre, which originates in bacteriophage P1 and targets short inverted sites 
called loxP, and FLP (flippase), taken from the 2-µ circle plasmid of 
Saccharomyces cerevisiae which targets FRT recognition sequence sites. These 
have been used widely for genomic integrations and rearrangements in 
bacteria and yeast. The advantage of these recombinases are that they are 
small in size, target short attachment sequences and require no cofactors for 
effective recombination. However, since they target and recombine two 
identical sites (loxP x loxP or FRT x FRT), these enzymes catalyse the reverse 
DNA excision reaction as well as the integration reaction. This is due to the 
fact that the recombinant product sites have the same sequence as the target 
substrate sites, and means that genomic integrations using these 
recombinases don’t always show the high efficiencies demanded in synthetic 
biology.  
The Cre-loxP system has been used extensively for gene deletions, 
rearrangements and heterologous gene integrations, mostly in eukaryotic cells 
(Sauer, 1998). Another use of the Cre-loxP system has been the the secondary 
removal of marker genes or plasmid backbone after integration into the 
genome (Martinez-Morales, 1999). However, most recombinase-mediated 
genomic integration methods in E. coli have involved the integration of whole 
plasmids into naturally-occurring target sites on the genome. Several other 
phage recombinases have been demonstrated to do this in E. coli, including 
the λ, HK022, φ80, P21, and P22 phages (Haldimann & Wanner, 2001).  
The use of recombinases for genomic integrations in E. coli has also been 
developed into a recombinase-mediated cassette exchange (RMCE) method, 
which replaces a target cassette on the chromosome flanked by two non-
compatible, or ‘heterospecific’ attachment sites, with a plasmid-borne 
cassette featuring two corresponding attachment sites. This was first done 
with FLP recombinase and heterospecific FRT target sites in mammalian cells 
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(Shlake & Bode, 1994). However, this method relies on the incompatibility of 
the two non-identical FRT sites variants, which can sometimes recombine and 
cause loss of the target cassettes from the genome or the delivery plasmid 
once FLP recombinase is introduced. The RMCE method has been 
demonstrated for both FLP and Cre (Turan et al., 2011). 
1.2.2.3.  CRISPR-Cas9 
In recent years, CRISPR-Cas9 has become an important tool for genome 
editing, particularly in eukaryote cells. The system makes use of the Cas9 DNA 
endonuclease derived from CRISPR (clustered regularly interspaced short 
palindromic repeats) bacterial immune systems. The Cas9 endonuclease cuts 
at sequences specified by its associated guide RNA, creating a double strand 
break that must be repaired by native cell machinery. Naturally, the Cas 
protein is guided by two CRISPR RNAs, however in seminal work by Jinek et al 
(2012) these RNAs were fused to create a single guide RNA (sgRNA) that 
simplified the system for use in genome engineering. The introduced break 
can then be repaired by non-homologous end joining (NHEJ) to create 
mutations at the target site, or homology directed repair (HDR) which 
introduces donor DNA into the break site (Wang et al., 2016). The power of 
Cas9 as a genome editing tool lies in the ability to synthesise sgRNA to specify 
the sequence at which it will cut, therefore making the system highly 
programmable and able to introduce mutations or new DNA at any site of 
choosing. For an excellent review of the wide applications and potential of 
CRISPR-Cas9 for genome editing in eukaryotes see Wang et al, 2016. 
The precise and programmable nature of CRISPR-Cas9 have made it a 
revolutionary tool for genome editing. However, there are still issues with off-
target effects due to the small size of the 20 bp sgRNA which can show 
homology with other sequences present on the genome, as well as other 
problems with efficiency and delivery (these shortcomings are reviewed by 
Peng et al, 2016). Most of the successful applications of CRISPR-Cas9 have 
been based on introducing point mutations into the genome by non-
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homologous end joining, rather than the introduction of long stretches of new 
DNA, which is the objective of the serine integrase system in this thesis.  
While most CRISPR-Cas9 work has focussed on gene editing in eukaryote cells, 
the system has also been developed for high-efficiency gene editing in E. coli. 
In 2013, it was demonstrated that the CRISPR-Cas9 system could be applied in 
E. coli and Streptococcus pneumoniae cells to introduce marker free 
mutations via homology directed repair (Jiang et al., 2013). Since then 
CRISPR-Cas9 gene editing in E. coli has been further enhanced by coupling the 
mechanism with lambda recombinase-mediated homologous recombination 
(recombineering), creating a high-efficiency method for mutating multiple 
genes with accuracy, a method that was also first suggested by Jiang et al 
(2013). 
Of particular relevance to the work in this thesis, the coupling of CRISPR-Cas9 
to lambda recombinase-mediated homologous recombination 
(recombineering) in E. coli has led to development of methods for more 
effective integration of large stretches of heterologous DNA. In 2015, Pyne et 
al. demonstrated the ability of the CRISPR-recombineering method to 
integrate PCR products of up to 3 kb at efficiencies that allowed successful 
mutants to be identified by colony PCR. More recently, Bassalo et al. (2017) 
demonstrated that their CRISPR-recombineering method was able to integrate 
a large markerless pathway (for isobutanol production) of around 10 kb into 
different sites on the genome at an efficiency of around 50%. 
CRISPR has also been used to improve efficiency of gene integrations in yeast. 
Introducing highly specific double strand breaks in S. cerevisiae has been 
shown to promote homologous recombination (in yeast a much more powerful 
native mechanism than that of E. coli) and therefore improves integration of 
introduced homology-flanked linear DNA (Storici et al., 2003). Recently, the 
use of CRISPR has been shown to achieve very high efficiencies of gene 
integrations at several sites on the S. cerevisiae genome by combining it with 
the genome engineering tool EasyClone (Ronda et al., 2015). 
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1.2.3.  Limitations and challenges 
The primary shortcomings of most genomic integration methods are the low 
integration rates achieved and propensity for off-site errors. These outcomes 
mean that there is a requirement for time-consuming screening processes 
following the integration protocol to ensure that the target gene has 
integrated correctly and only in the target location. The most commonly used 
genomic integration method used in E. coli, λ Red-mediated homologous 
recombination, in particular generally has low efficiencies, which are 
dependent on the size of DNA to be integrated and the length of the flanking 
homologous sequences (Wang et al, 2009; Mosberg et al, 2012). For all its 
promise, CRISPR has often been limited in its application in E. coli due to the 
organisms poor ability to repair double strand breaks, which results in 
lethality (Luo et al., 2016), as well as its tendency off-target activity, low 
efficiencies for long DNA sequence integrations and issues with Cas9 activity 
(Peng et al, 2016). 
Low efficiencies of genomic integrations from existing methods for the most 
part mean that a marker or selection gene must always be included in the 
insert, which is undesirable in some strain development contexts. The tools 
that overcome these problems, such as phage-mediated recombinations, are 
mostly limited to naturally-occurring attachment sites and have usually been 
used to integrate entire plasmids rather than single genes. Even these 
recombination methods are not completely efficient, as the enzyme that 
facilitates integration of the target DNA also catalyses the reverse excision in 
a bidirectional reaction, meaning that a very high concentration of donor 
plasmid is required for effective integration. Therefore there is still clearly a 
demand for a unidirectional genomic integration method that is capable of 
high efficiency integrations of markerless target DNA into a chosen location on 
the genome. 
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1.3  Serine integrases as tools for synthetic biology 
1.3.1.  Serine integrases 
Serine integrases represent a potentially powerful and flexible tool for 
synthetic biology and the genomic integration of heterologous genes. They 
belong to the serine recombinases, one of two families of site-specific 
recombinases alongside the tyrosine recombinases (which includes Cre, FLP 
and λ), both named and organised according to the amino acid residue that 
bonds to the DNA during catalysis (Grindley et al., 2006). The majority of 
known serine integrases belong to bacteriophages, which use these enzymes 
to incorporate bacteriophage DNA into its bacterial host genome. However, 
serine integrases have also been discovered to function in the transfer of 
antibiotic resistance genes via transposon (Wang & Mullany, 2000) or other 
genetic elements (Katayama et al., 2000). 
In their natural bacteriophage context, serine integrases bind to attachment 
sites attB and attP, on the bacterial and phage genomes respectively, 
catalysing the integration of the phage genome and producing two product 
sites, attL (‘Left’ of the integrated DNA) and attR (‘Right’ of the integrated 
DNA). These attL and attR sites consist of two half sites from the attP and 
attB sites (Figure 1.2). The integrase also catalyses excision of the prophage 
from the bacterial genome but only in the presence of the integrase’s 
recombination directionality factor (RDF), a phage-encoded protein which 
facilitates recombination between integration product sites attL and attR in a 
reverse reaction. A diagram representing this integration/excision of phage 
DNA is shown in Figure 1.2. 
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Figure 1.2: Simple diagram illustrating how serine integrases recombine an 
attP and attB site to integrate phage DNA into the bacterial chromosome to 
form product sites attL (‘Left’) and attR (‘Right’). The attL product site 
consists of a half-site from attB, B I (blue), and a half site from attP, P II 
(purple), while attR is made up of the other two half sites, P I (purple) and B II 
(blue). The recombination reaction between these sites to excise the 
prophage can only occur in the presence of the serine integrase’s 
recombination directionality factor (RDF). 
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1.3.1.1  Structure of the serine integrases 
Serine integrases, such as the Streptomyces bacteriophage φC31 integrase of 
focus in much of this work, generally consist of a catalytic N-terminal region 
of around 130 to 150 amino acids and a much larger C-terminal region of 
between 300 and 500 amino acids, which is involved in the targeting and 
binding of attachment site sequences (Smith and Thorpe, 2002). These two 
regions are connected by a long helix (αE) which is significantly involved in 
dimerisation, tetramerisation and DNA-binding during recombination 
(Rutherford & Van Duyne, 2014).  
  
While initial studies on serine integrases focussed on the integration activity 
and biochemical characteristics of the enzymes, actual structural and 
mechanistic details of their activity weren’t established until more recently. 
The structure of the C-terminal region was first revealed in a 2013 study by 
Rutherford et al, which examined the structure of the Listeria innocua 
prophage LI integrase bound to its attP half-site. This C-terminal region, 
which is involved in most of the integrase’s DNA-binding activity, can be 
considered to comprise two DNA-binding domains: the ‘recombinase domain’ 
and the zinc ribbon domain (Van Duyne and Rutherford, 2013). Within the zinc 
ribbon domain is an extended coiled-coil motif which has important function 
in recombination directionality (described below). Figure 1.3 shows how these 
structures are defined in six serine integrases according to alignment with 
A118 integrase, the crystal structure of which was identified as an integrase-
attP half-site complex by Rutherford et al. (2013). 
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Figure 3. Alignment of LSR protein sequences. Secondary structure assignments are based on the TP901 integrase catalytic domain structure (Yuan
et al., 2008) and the A118 integrase/attP half-site complex (Rutherford et al., 2013). The integrase used for the complex structure is 98% identical to the
A118 integrase sequence described by Loessner et al. (2000) that is shown here. References for the LSRs shown are given in Table 1. The sequence of
the small serine recombinase g!-resolvase is included for comparison. Residues identical in three out of the seven LSRs shown are shaded. Conserved
catalytic residues and zinc-coordinating cysteines are in boldface type. This figure is colored in the on-line version of this article, where conserved
residues are highlighted in yellow and conserved catalytic residues and zinc-coordinating cysteines are highlighted in magenta. (see colour version of
this figure at www.informahealthcare.com/bmg).
DOI: 10.3109/10409238.2013.831807 LSR domain structure and DNA binding 479
Figure 1.3: Alignment of protein sequences of seven serine integrases: A118, φC31, 
Bxb1, TP901-1, φRV1, R4 and Tnpx. Secondary structures labelled here are based 
on the above-mentioned structural studies on the TP901-1 C-terminal domain (Yuan 
et al., 2008) and A118/attP half-site complex (Rutherford et al., 2013) in 
conjunction with the A118 integrase sequence identified by Loessner et al. (2000). 
Residues that are conserved in three or more of these integrases are shaded, with 
conserved catalytic residues and zinc-coordinating cysteines in bold. Image: Van 
Duyne and Rutherford, 2013.
The structure of the serine integrase catalytic N-terminal domain has been 
found to be very similar to that of the better-understood resolvase and 
invertase serine recombinases, such as Sin resolvase (Mouw et al., 2008). 
Evidence for this has come from elucidations of the structure of the 
tetrameric form of TP901-1 integrase (Yuan et al., 2008), and two-domain 
structure of φC31 integrase (Rutherford & Van Duyne, 2014). 
To illustrate the general overall structure of the serine integrases, the 
tetrameric structure of TP901 integrase (as it is during synapsis) established 
by Yuan et al. is shown in Figure 1.4, while the dimeric structure of the TP901 
C-terminal domain (as it is when it binds to the attachment site DNA before 
forming a tetramer for synapsis) is shown in Figure 1.5 (Van Duyne and 
Rutherford, 2013). These can be considered alongside the further structural 
and sequence information shown in Figure 1.3. 
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Figure 1.4:  Tetrameric structure of the TP901 integrase. The catalytic C-terminal 
domain (Cterm) DNA-targeting N-terminal domain (Nterm) are labelled. See also 
protein sequence and structural annotation in Figure 1.3. Image: Yuan et al., 2008.
structure is likely to be shared by all family members.
In Figure 3, we have combined multiple sequence alignments
(Thompson et al., 1994), secondary structure predictions
(Kelley & Sternberg, 2009), and analyses of the TP901 and
A118 integrase structures to align the sequences of the first
seven LSRs listed in Table 1. The g!-resolvase sequence is
included as a representative small serine recombinase for
comparison.
The range in domain sizes among the LSRs that function
as phage integrases can be accounted for by insertions
between conserved secondary structural elements. This can be
most readily seen for the ’C31 integrase, where relatively
large inserts between b6 and b7 and after b9 could either
extend the length of the strands and/or introduce additional
small structural elements. In this case, the overall effect is an
increase in the size of the recombinase domain while
maintaining the conserved core structure. The TnpX transpo-
sase has a conserved three-domain region that is largely
indistinguishable from the phage integrases and a !170
residue cysteine-rich region that follows the conserved zinc
ribbon domain. The C-terminal 110 residues can be deleted
without loss of function in TnpX (Adams et al., 2004).
The catalytic domain
The sequence similarity between the LSR and small serine
recombinase catalytic domains suggested that these domains
would be structurally similar. The crystal structure of the
TP901 integrase catalytic domain confirmed that this was the
case and revealed a number of small differences that exist
between the two families (Figure 4). Most of these are simple
insertions between structural elements that increase the
average LSR catalytic domain size by 10–15 residues. The
serine nucleophile and three arginine residues that surround
the scissile phosphate during catalysis (Keenholtz et al., 2011)
are strictly conserved (indicated in Figures 3 nd 4), as is a
glu a ine residue in aA wh se side ch in is buried in an
unusual struct ral role. An acid c residue that lies near the
end of b2 is important for catalysis (Olorunniji & Stark, 2009)
and is also conserved, although the alignment is less clear in
this region for ’C31 integrase. Since the catalytic domain is
the only region of the LSRs that is reasonably well-
understood based on extensive studies of the small serine
recombinases, most functional studies have focused primarily
on other regions of the protein where less is known. However,
the effects of mutations to catalytic domain residues other
than the active site serine have been studied (Adams et al.,
2006; Liu et al., 2010; Rowley & Smith, 2008).
The aE helix
The aE helix plays a crucial role in the recombination
pathway, mediating inter-subunit interactions involved in both
LSR dimer formation and LSR tetramer formation. This helix
also plays an important role in the progression from synapsis
of attachment sites to DNA cleavage, subunit rotation and
DNA ligation to generate products (Stark et al., 2011).
Although normally considered part of the catalytic domain,
aE forms the bridge between the catalytic and recombinase
domains in the LSRs and plays an important role in DNA
binding. Like the rest of the catalytic domain, this region has
been less of a focus for LSR mechanistic studies. An
exception is an investigation of Val129 substitutions in the
’C31 integrase (Rowley & Smith, 2008). Val129 is located
at the N-terminal end of aE, in a position similar to that
of Ala117 in the TP901 integrase, where it is predicted to
be largely exposed to solvent in a catalytic domain dimer
(Figure 4). Substituting Ala or Gly for Val129 resulted in a
dramatic loss of recombination activity, but no change in the
efficiency of LSR binding to attB. Curiously, the V129A
integrase is deficient in attP x attB synapsis, while the V129G
integrase is proficient at synapsis but defective in DNA
cleavage. The lack of effect on DNA-binding is consistent
with small serine recombinase and TP901 catalytic domain
structural models, where no disruption of protein–protein
interactions would be expected in the context of integrase
dimers. The N-terminal base of aE is, however, expected to
play a significant role in mediating the tetrameric interface
that forms when two integrase dimers associate. It is
fascinating that a single methyl group (Ala versus Gly) is
able to differentially affect this aspect of the recombination
pathway, underscoring the fine-tuned nature of the LSR
catalytic domain. The authors also found that hyperactive
mutations in the integrase zinc ribbon domain that allow attL
x attR recombination (Rowley et al., 2008) were able to
restore a small amount of activity to the V129A and V129G
integrases, possibly by affecting a secondary protein–protein
interaction surface that stabilizes the synaptic complex.
In the small serine recombinases, the N-terminal half of aE
is an integral part of the catalytic domain, where it packs
against hydrophobic side chains from aD. The remainder of
aE interacts with the minor groove of DNA and connects to
the helix-turn-helix (HTH) DNA-binding domain via a short
linker (Yang & Steitz, 1995). In the LSRs, the C-terminal
segment of aE is an integral part of the recombinase domain.
Thus, this important structural element carries out functional
roles that involve three different levels of structure. At the
subunit level, portions of aE are devoted to interacting with
the catalytic domain, binding the minor groove of DNA, and
Figure 4. The LSR catalytic domain. The structure of the TP901
integrase catalytic domain dimer is shown (PDB code 3BVP). Conserved
catalytic residues are indicated as spheres at Ca and mark the location of
the active site pocket. Ala117 corresponds to the position of Val129 in
’C31 integrase. Selected secondary structural elements are labeled. This
figure is colored in the on-line version of this article, with catalytic
residues drawn as magenta spheres. (see colour version of this figure at
www.informahealthcare.com/bmg).
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Figure 1.5: Structure of the TP901 catalytic C-terminal domain as a dimer. Catalytic 
residues are represented by magenta spheres. Also indicated is the TP901 Ala117 which 
corresponds in po ition to Val129 in φC31 integrase (see Figure 1.3). Image: Van Duyne 
and Rutherford, 2013.
1.3.1.2  Serine integrase recombination mechanism 
In their review, Rutherford and Van Duyne (2014) collected the to-date 
evidence available on the serine integrase functional mechanism to propose a 
widely referenced and accepted model of integration. This serine integrase 
recombination model is shown in Figure 1.6. Upon recognition of its 
attachment site sequence, the integrase forms a dimer with another integrase 
unit, with each subunit bound to a half-site of the attachment site. See Figure 
1.5 for a structural illustration of TP901 integrase forming this dimer as it is 
when bound to its attachment site.  
A pair of attP and attB sites bound by integrase dimers are then brought 
together to form a tetramer. This complex, consisting of an integrase 
tetramer bound to the two attachment sites, is referred to as a synaptic 
complex (Grindley et al, 2006). The structure of an integrase subunit of TP901 
when in a tetrameric synaptic complex is shown in Figure 1.4. It is thought 
that the synaptic complex is stabilised by interaction of the zinc ribbon 
domain coiled-coil motifs of opposite integrase monomers (see Figure 1.6). 
Within the synaptic complex, DNA cleavage occurs to leave a 2 bp overhang at 
the centre of each attachment site sequence. Cleavage is followed by a 
vertical 180° rotation of two half-site-bound integrase subunits at odds with 
the rest of the synaptic complex in order to connect each attP half-site with 
its corresponding attB half-site. After this rotation, ligation occurs between 
the opposite attachment site half-sites in order to form the two 
recombination product sites attL (Left) and attR (Right) (Smith, 2015). 
The new attL and attR sites, still bound to integrase dimers, then dissociate 
from the synaptic complex. Following this, it is thought that the coiled-coil 
motifs within the zinc ribbon domain interact intra-molecularly in a way that 
prevents the reverse reaction between attL and attR from occurring, thus 
locking the dimer-attL/attR complexes and ensuring that the attP-attB 
reaction proceeds unidirectionally (Rutherford and Van Duyne, 2014). 
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1.3.1.3  Recombinase directionality factors (RDFs) 
For the reverse recombination reaction to occur between product sites attL 
and attR, serine integrases require the presence of their associated 
recombination directionality factor (RDF). RDFs are small proteins produced 
by the phage during its lytic cycle to excise the prophage from the host 
genome (Lewis and Hatful, 2001). It is not completely understood how RDFs 
interact with these attachment site-bound integrase dimers to activate attL-
attR recombination. However, it has been shown that some RDFs (e.g. φC31 
integrase and its RDF gp3) do not bind directly to the attachment site DNA, 
suggesting that they rather interact with the integrase to alter its 
conformation and activate excision (Khaleel et al., 2011). Studies on φC31 
integrase and Bxb1 integrase and their RDFs (gp3 and gp47, respectively) have 
revealed that these RDFs inhibit formation of attP-attB synaptic complexes as 
well as activating synapsis of attL-attR recombination (Ghosh et al., 2006; 
Khaleel et al., 2011). 
As described in Figure 1.6, it is thought that the coiled-coil motifs of integrase 
dimers, bound to attL and attR sites following the integration reaction, 
interact to prevent re-formation of the synaptic complex and therefore 
inhibiting the reverse attL-attR reaction. Rutherford and Van Duyne (2014) 
suggest that RDFs interact with the coiled-coil motif of the C-terminal domain 
to end inhibition of synapsis and activating recombination between attL and 
attR sites. Their model of this is shown in Figure 1.7. Evidence for this was 
published by Rowley at al (2008), who showed that φC31 integrase mutants 
with substitutions in the coiled-coil motif were able to catalyse attL-attR 
recombination without the presence of the φC31 RDF, gp3, suggesting that 
structural changes in this domain activate attL-attR recombination. 
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1.3.1.4  Attachment site sequence requirements 
As the integrase of mechanism of recombination relies on the exchange of two 
double-stranded DNA half-sites with 2 bp overhangs, it is a requirement of 
serine integrase recombination that the 2 bp overhangs of recombining attP 
and attB sites are complementary. If the central dinucleotide pairings of these 
sites are not the same, then ligation cannot occur after strand exchange, and 
the recombination mechanism cannot be completed. Work done by Ghosh et 
al (2003) on Bxb1 integrase revealed the importance of this central 2 bp 
pairing in the control of directional rearrangements. They suggested that 
orientation of recombination can be altered by changing this dinucleotide 
sequence as it does not affect binding to the att half-sites, but has a 
consequence on religation (Ghosh et al, 2003). This rule is integral to this 
project as it allows the use of multiple attachment site sequences, where only 
sites with matching central dinucleotide pairings are able to recombine. For 
example, an attP site with a TT central overhang can recombine with an attB 
site with a TT overhang, but is unable to recombine with an attB site 
containing a TC overhang. These combinations are shown further in Figure 
1.8. 
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1.3.1.5  Potential applications in synthetic biology 
Serine integrases have several characteristics which make them ideally suited 
to synthetic biology applications. Firstly, they have been shown to function in 
a highly unidirectional manner, proceeding with the reverse excision reaction 
between attL and attR only in the presence of the integrase’s RDF. This means 
that integration reactions are highly efficient, and sets them apart from other 
enzymes such as the tyrosine recombinases, which are not as strongly 
unidirectional and therefore less efficient.  
Secondly, the minimum attachment site sequences of both attP and attB 
required for efficient recombination by serine integrases are much shorter 
than those of other recombinases proposed for use in synthetic biology (see 
Table 1.1 for serine integrase minimum attachment site lengths). λ integrase 
for example requires a much larger attP site of 240 bp, despite having a small 
25-bp attB target site (Landy, 1989). These shorter attachment site pairs are 
appealing for synthetic biology applications as they shorten the length of 
required constructs and leave shorter ‘scar’ sites following recombination. 
Lastly, unlike tyrosine recombinases, serine integrases do not require auxiliary 
host factors to complete efficient recombination, further simplifying their use 
for synthetic biology in a range of organisms. Table 1.1 shows six commonly 
studied serine integrases that are considered possible candidates for use in 
synthetic biology, alongside their RDFs, and the minimum attachment site 
lengths required for efficient recombination. 
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The potential of serine integrases is expanded further due to the many 
different combinations of att sites can be utilised. Of the several serine 
integrases that are being used, each recognises its own att sites with high 
specificity. Then, for each integrase there are 6 possible exclusive attP and 
attB pairings, based on changes to the central 2 bp sequence (TT, CT, GT, CA, 
CC, TC). The site-specific nature of these enzymes and the array of 
possibilities of combination that attachment site modification can enable 
controlled switching, excision or cassette exchange of DNA on a host’s 
genome. 
In addition to the already growing list of serine integrases that are available 
for use in synthetic biology, chimeric integrases have also been shown to be 
functional in E. coli and human cells. In 2014, Farruggio and Calos created and 
successfully demonstrated φBT1-φC31 and φC31-TG1 hybrids, which 
recombined hybrid att sites of both integrases, as well as native att sites in 
the case of φBT1-φC31 chimeras (Farruggio & Calos, 2014). While this was the 
first study to demonstrate successful activity of serine integrase hybrids, it 
also opens up the possibility of generating many more chimeras which could 
also be used in a possible multi-integrase synthetic biology toolkit, targeting 
newly created hybrid sites to further expand the list of att site combinations 
available. 
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1.3.2.  Current uses 
1.3.2.1.  Serine integrase recombinational assembly (SIRA) 
Serine integrases are already being applied in synthetic biology for 
recombinational plasmid and pathway assembly. The serine integrase 
recombinational assembly (SIRA) method makes use of the specificity of serine 
integrases for recombining only sites with matching central dinucleotide 
pairings to assemble multiple DNA fragments in a one-pot reaction (Colloms et 
al., 2013). According to the six possible central dinucleotide pairings possible 
(TT, CT, GT, CA, CC, TC), up to six gene fragments flanked by different attB 
and attP sites can be assembled into a circular plasmid in a single reaction 
with one integrase. Development of this method to incorporate multiple 
integrases in a one-pot assembly is also further expanding the number of parts 
it is possible to assemble at once. 
1.3.2.2.  Serine integrase-mediated genomic integrations 
Of focus in this study is the use of serine integrases for rapidly and efficiently 
integrating heterologous DNA into a host organism’s genome. Due to the 
unidirectional nature of serine integrases and their high specificity for small 
attachment sites, they are ideally suited for use in genomic integrations. Most 
genome editing research using serine integrases in heterologous organisms has 
focused on mammalian cells. Several serine integrases have been 
demonstrated to effectively insert plasmid DNA into either natural att-like 
pseudo-sites found on mammalian genomes or pre-inserted att sites, including 
φC31 integrase (Thyagarajan et al., 2001), Bxb1 integrase (Russel et al., 
2006), φBT1 integrase (Xu et al., 2008) and R4 integrase (Olivares et al., 
2001). 
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However, despite extensive demonstration of the utility of serine integrases 
for genomic integrations in mammalian cells, there have been comparatively 
few applications of these enzymes for genome engineering in bacteria. In 
2009, Morita et al first demonstrated intramolecular recombination in E. coli 
cells using the serine integrase TG1 to recombine TG1 attP and attB sites 
across a plasmid substrate in vivo (Morita et al., 2009). Following this, they 
developed a TG1 integrase-based system for the genomic integration of a 
plasmid in E. coli, by first inserting either an attP or attB site into the host 
genome and demonstrating integration of a non-replicating plasmid containing 
the corresponding att site under expression of TG1 integrase. They did this 
first with a 2 kbp size plasmid (Hirano et al., 2011) and later with a much 
larger plasmid of 10 kbp in size (Muroi et al., 2013) with a high efficiency of 
~104 transformants per µg of DNA, showing that increasing sizes of DNA can be 
integrated with little loss of efficiency. 
1.4.  A serine integrase-based genomic landing pad 
system 
1.4.1.  Landing pad design 
This work focused on the design of a novel system in which two serine 
integrase attachment sites were introduced into the E. coli genome as an 
insert featuring an antibiotic resistance marker gene; this construct is 
referred to here as a ‘landing pad’. This differs from previous studies in which 
only a single attachment site on the genome was used to integrate whole 
plasmid DNA. While the latter is useful for some modes of study, in synthetic 
biology it is desirable to insert a heterologous gene (or multi-gene construct) 
into the genome at a known location and in the desired orientation without 
leaving behind unnecessary markers or other plasmid vector genes.  
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The landing pad system in this project was designed to incorporate a marker 
gene flanked by two integrase attB target sites with alternate central 
dinucleotides. A ‘donor’ cassette featuring the gene to be incorporated 
flanked by the corresponding attP sites can then be introduced concomitant 
with the expression of the integrase enzyme to facilitate cassette exchange. A 
diagram illustrating this landing pad system is shown in Figure 1.9. The 
decision to differ the central dinucleotides of each of these sites is based on 
the requirement of att sites to have complementary 2 base overhangs for re-
ligation following cleavage and strand exchange in the synaptic complex. For 
example, a TT central dinucleotide attB will only successfully recombine with 
a similarly TT central dinucleotide attB, and the same for TC, CT, GT, CA and 
CC (see Figure 1.8). There are therefore six useful variants of each attB-attP 
combination for every integrase. Therefore, the result of using two non-
identical attB sequences as part of the landing pad is that cassette exchange 
occurs efficiently only in the orientation specified. 
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 Figure 1.9: The landing pad (LP) system consists of a marker gene flanked by 
two attB sites with non-identical central dinucleotides, attBTT and attBTC, pre-
established on the chromosome via homologous recombination. Under 
expression of the integrase enzyme, a donor cassette featuring the transgene 
to be introduced onto the genome flanked by attP sites corresponding to the 
LP attB sites (attPTT and attPTC) is introduced. Recombination between the 
matching att sites results in cassette exchange at the LP site, leaving the 
transgene on the genome, flanked by recombination product sites attLTT and 
attLTC. In this double recombination event the marker gene is removed from 
the genome, alongside the corresponding recombination product sites attRTT 
and attRTC. See Figure 1.2 for clarification of product site formation. 
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1.4.2.  Potential for highly efficient markerless genomic 
integrations 
Given the high efficiency of cassette exchange that could be possible using 
the landing pad system, there is potential for this mechanism to incorporate 
target genes without the need for an accompanying marker gene, therefore 
eliminating the need for a selective marker screening step and expediting the 
strain development process. If efficiencies prove to be high enough, it may be 
possible to transform a target gene donor cassette without a marker gene into 
the landing pad cells while expressing the integrase enzyme and assume that 
the colonies obtained from this transformation will have performed successful 
cassette exchange, placing the target gene in the known LP location. For 
confirmation of the integration, the known genomic location could simply 
then be sequenced to check for the desired outcome. In this system, the 
primary limitation would be the initial integration of the LP attB sites, which 
must be done using less efficient homologous recombination methods and 
requiring markers. However, once LP sites have been established, these 
strains could be used confidently for integration of markerless cassettes. 
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1.4.3.  Towards a multi-integrase toolkit for whole pathway 
integration and strain optimisation 
Due to the increasing list of integrases available for use in synthetic biology 
(see Table 1.1), there is an opportunity to create an expanded toolkit of 
multiple integrase landing pads. A single strain of E. coli or other industrially 
relevant microorganism could be created with a landing pad for each 
integrase, providing the opportunity to integrate multiple genes of an entire 
biochemical pathway at separate genetic loci. On top of this, three versions 
of the landing pad for each integrase could theoretically be created, featuring 
alternative combinations of att sites with two of the six possible central 
dinucleotide pairings (Figure 1.8). At each site the reverse cassette exchange 
reaction can also be performed, in which a donor cassette featuring two attR 
sites corresponding to the product attL sites of the original cassette exchange 
is introduced in the presence of the integrase and its RDF. This further 
increases the options and flexibility of this system for strain development and 
pathway optimisation. This secondary LP cassette exchange is described in 
Figure 1.10. However, for this tool to be developed successfully, several 
questions must be addressed in order to optimise efficiency of cassette 
exchange at the LP, establish several well characterised LP sites across the 
genome and ensure that several integrases could operate within the same 
system without cross-reactivity. 
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 Figure 1.10: Following initial cassette exchange of a heterologous gene into the LP 
site, a secondary cassette exchange reaction can be performed to replace the initial 
transgene with an alternative gene. This is done by introducing a new donor cassette 
featuring the alternative gene flanked by attR sites which correspond to the initial LP 
integration product attL sites. Under expression of both the integrase and its RDF, 
the reverse recombination excision reaction occurs between attL and attR sites, 
leaving the new alternative transgene on the genome flanked by attB sites. These 
attB sites can then be used again for cassette exchange of an attP-featuring donor 
cassette, continuing the flexibility provided by the LP system. 
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1.5.  Challenges for developing an effective multi-
integrase landing pad system 
1.5.1.  Determining the effect of genome position on landing 
pad integrations 
For a markerless landing pad system to be effective, high cassette exchange 
efficiencies of close to 100% are needed in order to be confident that a 
transgene introduced as a donor cassette has been successfully integrated 
without the need for the subsequent selective screening for which a marker is 
required. There is already some evidence that position on the E. coli genome 
affects the efficiency of integration of DNA at an introduced att site for TG1 
integrase (Muroi et al., 2013). Muroi et al (2013) pre-inserted attP sites at 
various sites across the E. coli genome, and were able to integrate an attB-
containing plasmid of around 10 kbp in size at an efficiency of close to 104 
transformants per µg of DNA. They found that integration occurred more 
efficiently at sites inserted closer to the E. coli replication origin site oriC and 
the E. coli centromere analogue migS, suggesting that this was due to DNA 
proximal to these locations being exposed more to the cytosol at the poles of 
the cell during chromosomal segregation. Frequencies of integrations were 
103-4 per µg of transformed plasmid for the sites in this region (dinD - yabP) 
compared to 102 per µg of DNA elsewhere on the genome. Therefore it will be 
interesting to see whether the efficiency of integration at an LP site is 
increased further when present in this part of the genome. To investigate this, 
LPs should be tested at many sites across the E. coli genome, in mutants 
generated by random transposition of the attB LP cassette. 
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Using this set of E. coli LP mutants, the variability in expression levels of the 
transgene could then also be measured at each different site, providing 
information that could allow an LP mutant to be selected for heterologous 
gene integration based on the final expression levels required of the product. 
Genomic location has been shown to have considerable effect on gene 
expression levels in E. coli. Previously, Englaender et al (2017) showed that 
expression levels differed from 25% to 500% of the expression levels of the 
same gene from a high-copy number plasmid across four different integration 
sites on the E. coli genome. Previous reports support this, with Bryant et al 
(2014) also showing that position on the chromosome can have a 300-fold 
effect on expression levels of a GFP reporter. A similar measure of expression, 
using GFP, can be used here to measure expression levels at each randomly-
transposed LP site after integration of a GFP-featuring integration cassette. 
Orientation of a gene on the genome has also been shown to have an effect on 
expression levels (Block et al, 2012), and this will also be taken into account 
when contrasting expression levels of an integrated GFP gene at each 
randomly transposed LP site on the E. coli genome. 
1.5.2.  Methods for target gene delivery to the landing pad 
The method for delivery of a transgene to be integrated into the genome is a 
challenge that will be addressed in this project. In initial iterations of phage 
recombinase-mediated genomic integrations, whole plasmids were integrated 
at single target sites. Following on from this, plasmid-based cassette 
exchange methods were then used such as RMCE, in which two non-identical 
attachment sites flanked a donor cassette on a plasmid, inserting the target 
gene into a corresponding two-site target cassette on the genome in the 
desired orientation (Turan et al., 2011).  
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The most desirable system for delivery of a target gene is via a linear PCR 
product. This would allow a simple system in which a target gene to be 
introduced could be amplified by PCR with the two flanking attachment site 
sequences incorporated via the PCR primers, before transforming this cells 
with this PCR product. However, transforming cells with linear DNA poses 
problems due to the activity of endonucleases in the E. coli cell such as the 
RecBCD helicase-nuclease which degrades linear DNA (Dillingham & 
Kowalczykowski, 2008). Therefore, this project will first devise and 
implement a method of delivery for the landing pad ‘donor cassette’ in order 
to demonstrate the landing pad system, before later going on to focus on 
possible protocol for delivery via a linear donor cassette in the form of a PCR 
product. 
1.5.3.  Orthogonality of serine integrases and their RDFs 
In order to develop a multi-integrase landing pad system, there must be 
minimal cross-reactivity between the different integrases, their RDFs and 
attachment sites. A multi-LP cell would have sites for several integrases, and 
therefore for a transgene to be integrated into the correct LP location as 
desired, there must be a confidence that an integrase will not recombine the 
sites of another integrase. This could give rise to the transgene being 
unintentionally integrated into more than one site on the genome. Therefore 
the fidelity of each integrase to its own attachment sites, the extent to which 
central dinucleotide pairs direct correct recombination and the orthogonality 
of integrases and their RDFs will all be investigated, beginning with the latter.  
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The LP system allows for flexible switching of genes in the genomic LP site, 
which can be of use when optimising a pathway or testing multiple versions of 
a possible heterologous gene. For example, following the integration of an 
initial transgene into an LP, an alternative or mutated gene could then be 
swapped in directly to replace the initially introduced gene. This could be of 
advantage for quickly testing different combinations of genes within a 
pathway during strain expression optimisation. Once the original donor 
cassette has been integrated at the LP site via recombination of attP and attB 
sites, two non-identical attL sites (with differing central dinucleotide pairs) 
are left on the genome flanking the integrated gene. These attL sites can be 
used in another cassette exchange reaction, integrating a donor cassette 
flanked by corresponding attR sites. This then leaves behind two attB sites as 
they existed on the original LP cassette. A diagram of this secondary LP 
cassette exchange reaction is shown in Figure 1.10. 
In a multi-integrase system, the success of this chop-and-change mechanism 
depends on the fidelity of an integrase with its RDF. If an integrase was 
expressed in the cell for the ‘forward’ exchange reaction (attB x attP) when 
residual compatible RDF was present, cassette exchange efficiency could in 
theory be reduced as the RDF would activate the reverse reaction and the 
integrase would therefore no longer have the advantage of unidirectional 
efficiency. For the development of a successful multi-integrase landing pad 
system, the extent to which chosen integrases are cross-compatible in the 
above ways must be determined. Creating a protocol for sequential cassette 
exchanges at several integrase LPs will also be a major challenge, as it will 
require the expression and subsequent suppression of each integrase and RDF 
for secondary cassette switching. 
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1.6.  Project aims 
The foremost aim of this project was to demonstrate a landing pad for φC31 
integrase in E. coli. This involved designing the landing pad, inserting it into a 
defined location on the genome and measuring the efficiency of cassette 
exchange at this landing pad site. This work makes up the content of Chapter 
3 of this thesis. Specific objectives include:    
• Designing a landing pad cassette for φC31 integrase and selecting an 
appropriate location on the genome into which it will be inserted. 
• Synthesising a cassette containing this LP sequence with flanking homology 
to the target site. 
• Inserting the φC31 integrase into the E. coli genome via recombineering. 
• Confirmation of insertion of the φC31 LP into the genome by selective 
screening and colony PCR. 
• Design and construction of a ‘donor cassette’, and development of an 
effective delivery method that allows for detection transformation and 
cassette exchange. 
• Measurement of cassette exchange efficiency at this φC31 LP site. Note: 
cassette exchange efficiency is defined throughout this thesis as the 
percentage of cells (colonies) in which cassette exchange reaction has 
taken place across the LP, as a proportion of the number of cells that have 
been successfully transformed with the donor cassette DNA (colonies 
selecting positive for donor cassette transformation). 
• Establish and test a Bxb1 integrase LP in the same design as the φC31 
integrase  LP. 
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After the φC31 integrase LP has been demonstrated in a single location on the 
genome, LPs will be established at multiple locations on the E. coli genome in 
order to measure the relative efficiency of different genomic loci, with a view 
to development of a multiplexed landing pad system. This work makes up the 
content of Chapter 4 of this thesis. Specific objectives include: 
• Inserting the φC31 integrase LP at several locations on the E. coli genome 
by random transposition. 
• Confirming and characterising the genomic locations of a section of the 
φC31 LP mutant library generated by random transposition, and selecting 
several φC31 LP mutants to represent a diversity of LP locations across the 
entire genome. 
• Measuring the efficiency of cassette exchange at each of these selected 
φC31 LP strains to determine whether genomic location has an effect on 
recombination and LP cassette exchange efficiency. 
• LP sites can be further characterised by measuring expression levels at 
each genomic locus, by inserting a fluorescent protein gene into the LP via 
cassette exchange and measuring fluorescence. 
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Another aim of the project was to determine the extent to which closely 
related integrases and their RDFs are capable of interacting. φC31 integrase 
and TG1 integrase, which share a high percentage of sequence homology, will 
first be tested to see whether they interact with each integrase’s RDFs. This 
work makes up the content of Chapter 5 of this thesis. In vitro recombination 
assays, in which a plasmid substrate containing two corresponding attachment 
sites is incubated with the integrase (with or without RDF), with 
recombination resulting in the production of two smaller plasmids, will be 
used to investigate the following: 
• To what extent TG1 RDF gp25 is capable of activating φC31 attL-attR 
recombination 
• To what extent φC31 RDF gp3 is capable of activating TG1 attL-attR 
recombination 
• To what extent TG1 RDF gp25 is capable of inhibiting φC31 attP-attB 
recombination 
• To what extent φC31 RDF gp3 is capable of inhibiting TG1 attP-attB 
recombination 
The final aim of the project was to export the φC31 integrase LP 
demonstrated in E. coli into the simple eukaryotic host Saccharomyces 
cerevisiae. This involves designing host-appropriate selections to replace the 
one used in E. coli, but with the same overall landing pad design. Using a 
mutant knockout yeast library, φC31 LPs will be established in several 
locations on the S. cerevisiae genome, and the relative cassette efficiencies 
between each will be measured. This work makes up the content of Chapter 6 
of this thesis. 
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2.  Chapter 2: Materials and Methods 
Chapter 2 details the methods used in this study. Section 2.1 to Section 2.5 
list the microbial strains, growth media, antibiotics, PCR primers and plasmids 
used or generated during this work. Sections 2.6 to 2.22 are divided into 
individual protocols used and are described to ensure reproducibility and 
clarity of experimental method. 
2.1.  Bacterial and yeast strains 
All Escherichia coli strains were derived from strain K-12 substrain MG1655. 
Reference names and genotypes of each strain used in this study are shown in 
Table 2.1. The Saccharomyces cerevisiae strains used in this study are derived 
from strain S288C, and are shown in Table 2.2. 
Table 2.1 : Escherichia coli strains used in this study. All stored as 
glycerol stocks (50% v/v) at - 70°C. 
E. coli  
Strain Name Genotype Reference
DS941 AB1157, recF, lacZ∆M15, lacIq
Summers & 
Sherratt, 
1988
π1 DH5α thyA::(erm-pir116) (ermR) Demarre et al, 2005
LPC311
AB1157, recF, lacZ∆M15, lacIq, 
pepA::φC31LP(ermR) This study
RTC31LP
AB1157, recF, lacZ∆M15, lacIq 
φC31LP(kanR,rpsL) This study
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Table 2.2 : Saccharomyces cerevisiae strain used in this study. Library 
stored in multi-well plate glycerol stocks (50% v/v) at - 80°C. 
2.2.  Growth media 
All growth media used in this study are listed in Table 2.3. 
Table 2.3 : Liquid and solid (agar) media used in this study 
S. cerevisiae 
Strain Name Genotype Reference
YKO (KanMX) Background strain Saccharomyces cerevisiae S288C
Giaever & 
Nislow, 2014
Name of 
Media Composition
Liquid LB
10 g tryptone, 5 g yeast extract, 5 g NaCl; made up to 1 L 
with distilled H2O and adjusted to pH 7.5 with NaOH
LB Agar Liquid LB plus 15 g / L agar
MacConkey 
Agar
8 g McConkey agar base, 180 mL distilled H2O, 10 mL 20% 
galactose (plus antibiotics as required)
Synthetic 
Defined 
(SD) Yeast 
Media
2% glucose, 6.7 g/L yeast nitrogen base, amino acids (20 
mg/L histidine, 120 mg/L leucine, 60 mg/L lysine, 20 mg/
L arginine, 20 mg/L tryptophan, 20 mg/L tyrosine, 40 
mg/L threonine, 20 mg/L methionine, 50 mg/L 
phenylalanine, 20 mg/L uracil, 20 mg/L adenine), [20 g/L 
agar for solid media]: add distilled H2O to 1 L and 
sterilised by autoclave
Yeast 
Extract 
Peptone 
Dextrose 
(YPD)
10 g yeast extract, 20 g bacto peptone, 20 g dextrose, 
[24 g agar for solid media]: added distilled H2O to 1 L and 
sterilise by autoclave
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2.3.  Antibiotics 
Antibiotics were used throughout this study to select for the 
following antibiotic-resistance makers on plasmids or cassette 
inserts: ApR (ampicillin-resistance), KmR (kanamycin-resistance), 
CmR (chloramphenicol-resistance) and EmR (erythromycin-
resistance). The antibiotics used with their working and stock 
concentrations are shown in Table 2.4. 
Table 2.4 : Antibiotics used in this study with working concentrations 
used for antibiotic marker selections in growth media and stock 
concentrations. 
Antibiotic Working Concentration Stock Concentration
Ampicillin 100 µg / mL 100 mg / mL in H2O
Kanamycin 50 µg / mL 50 mg / mL in H2O
Chloramphenicol 25 µg / mL 25 mg / mL in 100% EtOH
Erythromycin 200 µg / mL 50 mg / mL in 100% EtOH
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2.4.  PCR Primers 
The majority of primers used in this work were synthesised as 
oligonucleotides by Eurofins Genomics. For PCR and sequencing primers 
under 50 bp the following Eurofins synthesis specifications were used: 
Unmmodified DNA Oligo, 0.05 µmol synthesis scale, with High Purity Salt 
Free (HPSF) purification. Larger primers (over 50 bp) were synthesised 
by Integrated Gene Technologies (IDT) as Ultramer DNA Oligos, at a 
scale of 4 nmol, with High Performance Liquid Chromatography (HPLC) 
purification. All primers used are shown in Table 2.5 in order of use 
throughout this work. 
Table 2.5 : Primers used in this study 
Name Size (bp) Sequence (5’ to 3’) Application
C31LP 
pepA 
For
123
ATTCTATCTGTAGCCACCGCCGTTGTC
TTTAAGATTCAGGAACGTAGTGCGTG
CGGGTGCCAGGGCGTGCCCTTGGGC
TCCCCGGGCGCGTACTCCCTTAGAAG
CAAACTTAAGAGTGTGTTG
Amplification of 
PepAC31LP 
recombineering 
DNA fragment
C31LP 
pepA 
Rev
129
AATAGTTATCTATTATTTAACGGGAGG
AAATAAGGAGTACGCGCCCGGGGAGC
CCGAGGGCACGCCCTGGCACCCGCA
CAAACCGCGCTGGGTTTAACGGCGAA
GAGTAATTGCGTCAGGCAAGGCTGT
Amplification of 
PepAC31LP 
recombineering 
DNA fragment
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Upstr. 
pepA 
For
20 ACACGAAGTCATCGCAACAG
Confirmation 
PCRs at pepA/
LPC31 site 
(recombineering 
and cassette 
exchanges)
Dwnstr. 
pepA 
Rev
20 CTCATCGCCTGTGAAGATGA
LP confirmation 
PCRs (see above)
pepA  
For 18 GGAGAAACAGCGGAGTGC
LP confirmation 
PCRs (see above)
pepA 
Rev 19 AGCGTCTCTTTTGCCGTCT
LP confirmation 
PCRs (see above)
EmR  
For 15 GGAGGGATTCGTCAT
LP confirmation 
PCRs (see above)
EmR  
Rev 15 TATGGCGGGTAAGTT
LP confirmation 
PCRs (see above)
CmR 
Rev 20 GGGCGAAGAAGTTGTCCATA
LP confirmation 
PCRs (see above)
KmR  
For 20 TTGGGTGGAGAGGCTATTCG
LP confirmation 
PCRs (see above)
KmR  
Rev 20 AATATCACGGGTAGCCAACG
LP confirmation 
PCRs (see above)
C31LP 
Donor 
For
90
CGGCGGAAGCTTGTAGTGCCCCAACT
GGGGTAACCTTTGAGTTCTCTCAGTT
GGGGGCGTAGGCTAGCAAGAGGTTC
CAACTTTCACCAT
Amplification of 
KmR/CmR 
φC31LP donor 
cassette for 
pRM1/2/3
Name Size (bp) Sequence (5’ to 3’) Application
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C31LP 
Donor 
Rev
97
GCAGTTATTGGTGCCTAGAAAGCGGC
CGCCGGCCGCTACGCCCCCAACTGAG
AGAACTCGAAGGTTACCCCAGTTGGG
GCACTACGGTACCGCGGCC
Amplification of 
KmR/CmR 
φC31LP donor 
cassette for 
pRM1/2/3
C31LP 
EmR/
NheI 
Don For
37
CCCCCGCTAGCGAATTCCTTAGAAGC
AAACTTAAGAG
Amplification of 
an EmR φC31LP 
donor cassette 
for pRM4
C31LP 
EmR/
NotI 
Don Rev
39
AAAAAGCGGCCGCCTCGAG 
TTATTTCCTCCCGTTAAATA
Amplification of 
an EmR φC31LP 
donor cassette 
for pRM4
KAN3 21 GACCGCTTCCTCGTGCTTTAC
Arbitrary PCR 
(Methods 2.19)
KAN4 23 TCTATCGCCTTCTTGACGAGTTC
Arbitrary PCR 
(Methods 2.19)
ARB1 35
GGCCACGCGTCGACTAGTCANNNNN
NNNNNGATAT
Arb. PCRs (N = 
random base)
ARB2 20 GGCCACGCGTCGACTAGTCA
Arbitrary PCR 
(Methods 2.19)
RTLP3 
For 20 GTGCTGTCGTTCATACCGAC
Confirmation of 
RT LP 3 location
RTLP5 
For 20 ACATAGCCCTCATCTACCGC
Confirmation of 
RT LP 5 location
RTLP7 
For 20 TGGCTGTCTTTCGAACCTCT
Confirmation of 
RT LP 7 location
RTLP8 
For 20 GTGCTGGATGGGCTGTATTG
Confirmation of 
RT LP 8 location
RTLP9 
For 20 CTTAACGCCTCTTCATCCGC
Confirmation of 
RT LP 9 location
Name Size (bp) Sequence (5’ to 3’) Application
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2.5.  Plasmids 
Plasmids created during this study were made through a combination of 
restriction digest and ligations from existing plasmids and PCR products. 
Further details on these methods can be found later in this chapter. All 
plasmids produced and used during this study are detailed in Table 2.6. The 
six plasmids constructed as part of this work are detailed further in Figures 
2.1 to 2.6. 
RTLP10 
For 20 CCTTCCAGTGACCATGTTGC
Confirmation of 
RT LP 10 location
M13  
Uni (-21) 18 TGTAAAACGACGGCCAGT
Sequencing 
plasmids
M13  
Rev 
(-29)
18 CAGGAAACAGCTATGACC
Sequencing 
plasmids
Yeast LP 
1F 20 GCGCGTACTCCACCTTCTAG
Confirmation of 
KanMX::URA3LP
Yeast LP 
2F 25 GAAACATGAAATTGCCCAGTATTCT
Confirmation of 
KanMX::URA3LP
Yeast LP 
1R 20 GGCCGCAGGTGGAGTACG
Confirmation of 
KanMX::URA3LP
Yeast LP 
2R 25 TATTGTTGGAAGAGGACTATTTGCA
Confirmation of 
KanMX::URA3LP
Name Size (bp) Sequence (5’ to 3’) Application
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Table 2.6: Plasmids used in this study 
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Plasmid Antibiotic Marker Description Source
pRM1 ApR
φC31LP donor temperature-
sensitive (repA101ts) plasmid; 
CmR cassette
This study 
(Figure 2.1)
pRM2 CmR
φC31LP donor temperature-
sensitive (repA101ts) plasmid; 
KmR cassette
This study 
(Figure 2.2)
pRM3 ApR
φC31LP donor temperature-
sensitive (repA101ts) plasmid; 
KmR cassette
This study 
(Figure 2.3)
pRM4 ApR
φC31LP donor temperature-
sensitive (repA101ts) plasmid; 
EmR cassette
This study 
(Figure 2.4)
pRM5 ApR
φC31 yeast LP delivery vector 
(homologous recombination); 
URA3 cassette marker; E. coli 
ColE1 vector
This study 
(Figure 2.5)
pFEM32 ApR
φC31 integrase expression  
plasmid (constitutive)
Femi 
Olorunniji
pFEM35 ApR
Bxb1 integrase expression  
plasmid (constitutive)
Femi 
Olorunniji
pKOBEG-A ApR
λ Red (gam, bet, exo) expression 
for recombineering; pBAD; 
RepA101ts 
Chaveroche 
et al., 2000
pKOBEG-C CmR
λ Red (gam, bet, exo) expression 
for recombineering; pBAD; 
RepA101ts 
Chaveroche 
et al., 2000
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Plasmid Antibiotic Marker Description Source
pSW23 CmR
Plasmid used as template for PCR 
amplification of φC31LP donor 
cassette marker (see pRM1)
Demarre 
et al, 2005
pSW29 KmR
Plasmid used as template for PCR 
amplification of φC31LP donor 
cassette marker (see pRM2 & RM3)
Demarre 
et al, 2005
pGD001 KmR GalK (MacConkey) assay substrate; 
φC31 integrase attP & attB sites
Femi 
Olorunniji
pZJ7 CmR φC31 integrase expression under 
pBAD (arabinose-induced); p15A ori
Jia Zhao
pZJ73 CmR
ISY100 plasmid for random 
transposition of KmR φC31 LP  
into the E. coli genome
Jia Zhao
pFM16 ApR in vitro recombination substrate; 
φC31 integrase attP & attB sites
Femi 
Olorunniji
pFM52 ApR
GalK (MacConkey) assay substrate; 
φC31 integrase attL & attR sites
Femi 
Olorunniji
pFM138 ApR GalK (MacConkey) assay substrate; 
TG1 integrase attP & attB sites
Femi 
Olorunniji
pFM139 ApR GalK (MacConkey) assay substrate; 
TG1 integrase attL & attR sites
Femi 
Olorunniji
pMTL23 ApR
E.coli cloning vector used for 
creation of yeast LP plasmid pRM5 
(see Figure 2.5); ColE1 origin
Chambers 
et al, 1988
Figure 2.1: pRM1, constructed in this study. This φC31 donor cassette (CmR 
flanked by attPTT and attPTC, PCR amplified from pSW23 using primers 
C31LP_Don_For & _Rev) was cloned into pKOBEG-A between restriction sites 
KpnI and HindIII. pRM1 features repA101-ts for temperature sensitivity (see 
Section 3.3.1). 
Figure 2.2: pRM2, constructed in this study. This φC31 donor cassette (KmR 
flanked by attPTT and attPTC, PCR amplified from pSW29 using primers 
C31LP_Don_For & _Rev) was cloned into pKOBEG-C between restriction sites 
KpnI and HindIII. pRM2 features repA101-ts for temperature sensitivity (see 
Section 3.3.1). 
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Figure 2.3: pRM3, constructed in this study. This φC31 donor cassette (KmR 
flanked by attPTT and attPTC, PCR amplified from pSW29 using primers 
C31LP_Don_For & _Rev) was cloned into pKOBEG-A between restriction sites 
KpnI and HindIII. pRM3 features repA101-ts for temperature sensitivity (see 
Section 3.3.1). 
Figure 2.4: pRM4, constructed in this study. This φC31 donor cassette (CmR 
flanked by attPTT and attPTC, PCR amplified from pSW23 using primers 
C31LP_Don_For & _Rev) was cloned into pKOBEG-A between restriction sites 
KpnI and HindIII. pRM4 features origin repA101-ts for temperature sensitivity 
(see Section 3.3.1). 
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Figure 2.5: pRM5, constructed in this study. This plasmid features the yeast 
φC31 LP consisting of a URA3 marker gene flanked by attachment sites attBTT 
and attBTC, surrounded by 150 base pairs of homology to the start and end of 
the KanMX gene for replacement by homologous recombination. The plasmid 
has a ColE1 origin for cloning and propagation in E. coli prior to 
transformation into yeast. 
Figure 2.6: pZJ73 was the plasmid used to generate the E. coli DS941 φC31 LP 
mutant library used in Chapter 5 via ISY100 random transposition. The φC31 
LP, consisting of a kanamycin resistance gene and counter-selectable rpsL 
marker flanked by attBTT and attBTC sites, placed between the two ISY100 
terminal inverted repeat sequences IRL and IRR, targets and inserts into the E. 
coli genome at any TA sequence (Urasaki et al, 2002). 
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2.6.  Restriction endonuclease digests 
Most digests were done using NEB endonucleases according to the 
manufacturer-recommended protocol. Digests were set up in microcentrifuge 
tubes containing the sample DNA in double distilled H2O, supplemented with 
the endonuclease manufacturers recommended buffer, with 2-10 units of 
enzyme per microgram of DNA. Samples were incubated for at least 1 hour in 
a water bath pre-heated to 37°C. 
2.7.  Ligation of plasmid DNA 
To ligate restriction digested fragments (from plasmid or PCR digests) during 
the cloning of new plasmids, the following standard protocol was used for 
ligation reactions with T4 ligase (NEB). In a microcentrifuge tube, linear 
digested DNA fragments were mixed with the NEB manufacturers 10x 
concentrated T4 buffer (volume for 1x final concentration) and made up to 
volume of 20 µL with double distilled H2O. The ligation mixture was incubated 
at room temperature (around 16°C) overnight. The following morning, 1-2 µL 
of this ligation mixture was used directly for transformation into 
electrocompetent E. coli cells, while the rest was saved for DNA purification 
by ethanol precipitation. 
2.8.  Ethanol precipitation 
The following ethanol precipitation protocol was used to purify and isolate 
DNA following ligations for plasmid cloning. To an overnight ligation reaction 
mixture, 0.22 volumes 5M ammonium acetate was added, followed by 2.5 
volumes 100% (v/v) ethanol, and vortexed vigorously before freezing 
overnight at -20°C. The DNA was then pellet by centrifugation at 13.2k rpm in 
a 4°C centrifuge for 60 minutes. The supernatant was very carefully removed, 
and the pellet washed in 80% (v/v) ethanol before centrifuging again for 30 
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minutes. The supernatant was then removed and the DNA pellet dried in a 
vacuum evaporator for 5 to 10 minutes. 20 µL of double distilled H2O was 
added to the pellet and vortexed vigorously before spinning down at 10k rpm 
for 2 minutes and cooling on ice for 5 minutes. This solution could then be 
stored at -20°C or used immediately for transformation into electrocompetent 
E. coli cells. 
2.9.  Standard transformations of E. coli cells  
2.9.1.  Chemical transformation 
For standard chemical transformation of plasmid DNA into E. coli cells, the 
following protocol was used. 0.4 mL of overnight growth culture was added to 
20 mL of sterile L-broth (LB) in a sterile 100 mL volume conical flask. This was 
incubated at 37°C for 90 minutes before being transferred to a centrifuge 
tube. Cells were centrifuged at 4°C at 7000 rpm for 4 minutes and the 
supernatant carefully discarded. 10 mL of ice-cold CaCl2 was added to the 
tube and the pellet carefully resuspended on ice. The CaCl2 cell resuspension 
was left on ice for one hour before repeating the above centrifugation step 
and discarding the supernatant. The remaining cell pellet was resuspended in 
1 mL CaCl2, and the chemically competent cells left on ice until needed for 
transformation.  
For each DNA transformation, 100 µL of the chemically competent cells was 
placed in a pre-chilled microcentrifuge tube, to which 1-2 µL of DNA was 
added, with flicking to mix. The cells and DNA were incubated on ice for 20 
minutes before being heat-shocked in a 37°C water bath for 5 minutes and 
replaced on ice for another 5 minutes to cool. 200 µL LB was added to the 
transformation mixture and incubated at 37°C (30°C for temperature-
sensitive (TS) plasmids) for 2 hours with shaking at 225 rpm. After this 
recovery incubation, 100-200 µL was spread on L-agar plates containing the 
appropriate antibiotic for selection of the plasmid backbone and the plates 
incubated overnight at 37°C (30°C for TS) to select for successfully 
transformed colonies. 
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2.9.2.  Electrotransformation 
Throughout this work, a high-efficiency electrotransformation protocol was 
used based on a transformation method recommended for λ Red 
recombineering (Chaveroche et al., 2000). Each electrotransformation was 
done as follows (with changes where noted). A colony of E. coli cells was 
inoculated into 5 mL of LB (with appropriate antibiotic) and grown overnight 
at 37°C (30°C for TS) with shaking at 225 rpm. In the morning, 0.5 mL of this 
overnight culture was added to two sterile 100 mL conical flasks containing 25 
mL LB (plus antibiotic). This was incubated at 37°C (30°C for TS), shaking at 
225 rpm, until an optical density OD600 of around 0.4 was reached (around 3 
hours of growth). The culture was then chilled in an ice-water slurry for 10 
minutes before being transferred to pre-chilled centrifuge tubes and 
centrifuged at 4°C for 7 minutes at 6500 x g. The supernatant was removed 
and the cell pellet carefully resuspended in 1 mL of ice-cold 10% glycerol (90% 
double distilled water, filter sterilised) on ice. Another 25 mL ice-cold 10% 
glycerol was added and the above centrifuge step was repeated. Cells were 
again resuspended in 1 mL ice-cold 10% glycerol plus another 25 mL and the 
centrifuge step repeated a third time. The cell pellet was again resuspended 
in 10% ice-cold glycerol and transferred to a pre-chilled microcentrifuge tube. 
This was centrifuged for 30 seconds at maximum speed in a microcentrifuge 
pre-chilled to 4°C and the supernatant was carefully discarded. Remaining 
cells were then resuspended in 200 µL ice-cold 10% glycerol. 
For the electrotransformation step, 40 µL of electrocompetent cells were 
transferred to a pre-chilled microcentrifuge tube. 1-2 µL of salt-free DNA was 
added and mixed by flicking. This mixture was then transferred to a pre-
chilled electrotransformation cuvette one ice. Cells were transformed in a 
MicroPulser electroporator using the EC2 setting (see product specifications 
for more details). After shocking, 1 mL of LB was immediately added and the 
broth-cell mix transferred to a sterile microcentrifuge tube. Tubes were 
incubated at 37°C (30°C for TS) with shaking at 225 rpm for at least 2 hours 
before spreading 100-200 µL of recovered cells onto L-agar containing 
appropriate antibiotics. Plates were then incubated at 37°C (or 30°C for TS) 
overnight to select for successfully transformed colonies. 
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2.10.  Agarose gel electrophoresis 
Agarose gels were used to separate out DNA according to size, from restriction 
digests or recombination assays. Agarose gels were made by adding agarose to 
TAE buffer (40 mM Tris/acetate, 1 mM EDTA, pH 8.5) for a final concentration 
of 1% agarose and heating in a microwave to completely dissolve. The heated 
liquid agarose was then left to cool before pouring into a gel electrophoresis 
dock containing a well-forming comb and being left to set. The comb was then 
removed and the gel submerged in TAE buffer before adding DNA samples 
(vortex-mixed with 6.25x concentrated loading dye to a final concentration of 
1x). The gel electrophoresis was run at a voltage of 80-120 V for 60-120 
minutes (or until loading dye had reached an appropriate place on the gel) 
before stopping and staining the gel. 
DNA in the gel was visualised by ultraviolet (UV) light using an ethidium 
bromide stain. After electrophoresis, gels were added to TAE buffer bath with 
added ethidium bromide at a 0.6 µg/mL concentration. The gels were then 
shaken gently in the ethidium bromide TAE solution for 30-60 minutes, before 
being rinsed and de-stained in TAE for a further 30-60 minutes to remove non 
DNA-bound ethidium bromide from the gel. DNA was then visualised using UV. 
For DNA fragments that were to be excised and purified for subsequent in 
vitro or in vivo work, agarose gels were placed on a 365 nm wavelength UV 
transilluminator so as to avoid too much UV damage to the DNA. For 
photography of the DNA on the agarose gels, a 254 UV transilluminator was 
used. 
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2.11.  Extraction of DNA from agarose gel 
For all DNA extractions from agarose gels, DNA fragments were visualised and 
excised using a scalpel on a 365 nm wavelength UV transilluminator. DNA was 
then purified from the excised gel using a QIAgen Gel Extraction Kit according 
to the manufacturers protocol.  
2.12.  DNA sequencing 
All sequencing was done by MWG Eurofins Genomics. DNA samples were 
prepared according to MWG Eurofins’ recommendations and dried in a vacuum 
evaporator before posting to Eurofins. If PCR primers were readily available in 
the lab, primer oligos were mixed with the plasmid samples in the 
concentration recommended by Eurofins prior to drying. Where possible, both 
3’ and 5’ strands of DNA were sequenced using forward and reverse primers, 
to doubly check intended ligations or integrations are as intended. 
2.13.  PCR reactions 
2.13.1.  NEB Phusion Polymerase method 
For PCRs with longer primers (such as the amplification of genes for 
recombineering featuring long additions of sequence homology), a modified 
NEB Phusion Polymerase protocol was used. Reactions were set up as follows: 
in a PCR tube mix 10 µL 5x NEB HF Polymerase Buffer, 5 µL 2mM (each) dNTP 
mix,  1 µL 50 mM MgCl2, 1.5 µL DMSO (3% final), 5 µL forward primer (5 µM), 5 
µL reverse primer (5 µM), 1 µL template DNA (for amplifying directly from a 
strain’s genome, 1 colony was transferred to 100 µL double distilled water and 
vortexed vigorously, before adding 1 µL of this to the PCR mix) and 22 µL 
double distilled water. The above mixture was vortexed before adding 1 µL 
NEB Phusion polymerase and vortexing again briefly. Reactions were then run 
through the following heat cycle: 1) 98°C for 60 seconds, 2) 98°C for 20 
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seconds, 3) 55°C for 30 seconds, 4) 72°C for 90 seconds, 5) repeat steps 2-4 
29 more times, 6) 72°C for 10 minutes. Reactions were then cooled at 4°C 
before either purifying by agarose gel electrophoresis and gel extraction, or 
using a QIAgen PCR Purification Kit (to avoid degradation by UV radiation).  
2.13.2.  Taq Polymerase method 
For simpler PCRs with shorter primers, an NEB 2x Taq Master Mix protocol was 
used, set up according to NEB recommendations. For amplifications from 
genomic DNA (as in cassette exchange confirmation PCRs), 1 colony was 
transferred to 100 µL double distilled water and vortexed vigorously, before 
adding 1 µL of this to the PCR mix. The following heat cycle was then used:  
1. 95°C for 30 seconds, 2. 95°C for 20 seconds, 3. 55°C for 30 seconds, 4. 
68°C for 90 seconds, 5. repeat steps 2-4 24 more times, 6. 68°C for 10 
minutes. Reactions were then cooled at 4°C and run on an agarose gel 
electrophoresis. 
2.14.  Purification of PCR product 
For most experiments, PCR products were purified by first running on an 
agarose gel, excising the DNA band from the gel on and extracting the DNA 
from the agarose using a QIAgen Gel Extraction Kit. However, in some cases it 
was necessary to avoid exposing the DNA to UV radiation (for example in order 
to improve efficiency of homologous recombination in recombineering), a 
QIAgen PCR Purification Kit was used. A small amount of the DNA yielded from 
this purification was then run on an agarose gel electrophoresis to confirm the 
size of the PCR product. 
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2.15.  λ Red recombineering 
The recombineering protocol was primarily based on the high-
electrotransformation method described in Methods 2.9.2 (Chaveroche et al., 
2000). E. coli DS941 was first chemically transformed with the λ Red 
expression plasmid pKOBEG-A (see Methods 2.5), with all consequent steps 
done at 30°C to maintain the temperature-sensitive pKOBEG vector.  
DS941/pKOBEG-A were grown for further electrotransformation as described 
in Method 2.9.2 with the addition of arabinose-induction of λ Red elements 
under control of the pBAD promoter. Cultures were grown at 37°C until they 
reached an OD600 of ~ 0.2, before adding 10% (w/v) L-arabinose (in filter 
sterilised double distilled water kept at 4°C) for a final concentration of 0.2% 
w/v. After induction cells were returned to a 37°C shaking incubator until a 
final OD600 of ~0.4 was reached.  
100 µL of high-efficiency electrocompetent E. coli DS941/pKOBEG-A cells were 
then transformed with 4 µL of the purified recombineering cassette PCR 
product. For the recombineering of LPC31 (replacing pepA with a φC31 
integrase attB LP with erythromycin-resistance marker EmR) this PCR product 
was amplified from E. coli strain π1 (EmR-positive) using primers 
C31LP_pepA_For and C31LP_pepA_Rev (Methods 2.4). It is important to note 
that during the development of this cassette exchange protocol, it was 
discovered that exposing PCR product to UV radiation (at the time of 
extraction from electrophoresis agarose gel) resulted in no integration of the 
PCR product by homologous recombination. Therefore in the final iteration of 
this protocol the PCR product DNA was purified directly from the PCR mixture 
using a QIAgen PCR Purification Kit. 
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2.16.  Clearing cells of temperature-sensitive plasmids 
Following transformations with temperature-sensitive plasmids (pKOBEG-A for 
recombineering or pRM plasmids for LP cassette exchanges), cells were 
cleared of the plasmids in the following method. Marker-positive 
transformants (selected according to the antibiotic marker being integrated 
into the genome) were chosen from transformation plates and transferred by 
toothpick to a 100-grid LB agar plate containing no antibiotic (100 
transformants), which was then incubated at 42°C overnight. The following 
day, each transformant patch was again transferred by toothpick to another 
100-grid LB agar plate containing no antibiotic and again incubated at 42°C 
overnight. Following this incubation, each temperature-treated transformant 
patch was transferred by toothpick to 100-grid agar plates containing 
different antibiotics to test for presence of the temperature-sensitive 
plasmid. For example, presence of pKOBEG-A would be tested for on LB agar 
plates containing ampicillin as this is the backbone marker of this plasmid. 
Additional selective plates would be selected to test for presence of the 
marker being integrated into the genome, and in the case of LP cassette 
exchange, for the marker gene being replaced on the LP. 
2.17.  Landing pad cassette exchange transformations 
Landing pad cassette exchange experiments were based on the high-efficiency 
electrotransformation protocol described in Method 2.9.2 (Chaveroche et al., 
2000). Initial cassette exchange transformations, in which a constitutive φC31 
integrase expression plasmid was used, were done as described in Method 
2.9.2. However, later cassette exchange protocols were done using an 
arabinose-inducible φC31 integrase expression plasmid, and followed the 
alterations described in Method 2.15 (for λ Red recombineering). Recovered 
cells after transformation were spread onto LB agar plates containing the 
antibiotic marker on the LP donor cassette, before curing the cells of 
temperature-sensitive donor plasmids as described in Method 2.16. 
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2.18.  ISY100 random transposition of LP in E. coli 
The ISY100-generated library of E. coli DS941 φC31 LP (KnR) mutants was 
generated in work done previously by this lab (E. Conte, manuscript in 
preparation). In brief, the ISY100 transposon protocol was done by introducing 
a plasmid which expresses ISY100 and features the LP cassette flanked by 
inverted repeat sites IRL30 and IRR30 (see Figure 2.6) into DS941 cells via a 
standard electrotransformation method. Successful integrations were selected 
on agar plates containing kanamycin which were then scraped and the 
resulting cell suspension used to create a glycerol stock library. 
2.19. Screening of random LP mutants by arbitrary PCR 
The arbitrary PCR method used in this study to confirm locations of randomly 
transposed φC31 LPs in the E. coli genome was adapted from a protocol 
described by Das et al (2005). The confirmations consist of a two-step PCR 
protocol, described further in Chapter 4. All primers used are described in 
Methods section 2.4, Table 2.5.  
The first PCR, which amplifies from an arbitrary sequence according to 
randomly generated sequences of primer ARB1 to a sequence within the 
kanamycin resistance gene of the φC31 LP, primer KAN3, was set up in the 
following Phusion polymerase reaction: 27.5 µL double distilled H2O, 10 µL 5x 
Phusion HF buffer, 2 µL 50 mM dNTPs, 2.5 µL 5 µM KAN3, 2.5 µL 50 µM ARB1, 5 
µL cell supernatant (1 LP mutant colony suspended in 50 µL double distilled 
H2O and boiled for 15 mins) and 0.5 µL Phusion polymerase. This reaction 
mixture was put into the following PCR machine heat cycle: 1) 95°C for 5 
minutes, 2) 94°C for 30 seconds, 3) 30°C for 30 seconds, 4) 72°C for 90 
seconds, 5) repeat steps 2-4 6 times, 6) 94°C for 30 seconds, 7) 55°C for 30 
seconds, 8) 72°C for 2 minutes, 9) repeat steps 6-8 30 times, 10) 72°C for 10 
minutes, 11) cooled at 4°C. 
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The second PCR step, which amplifies from a sequence within the ARB1 primer 
(primer ARB2) to a sequence within the LP kanamycin resistance gene but 
slightly downstream of primer KAN3 (primer KAN4), was set up in the 
following way: 31 µL double distilled H2O, 10 µL 5x Phusion HF buffer, 2 µL 50 
mM dNTPs, 2.5 µL 5 µM KAN4, 2.5 µL 5 µM ARB2, 1.5 µL of the first PCR 
reaction and 0.5 µL Phusion polymerase. This reaction mixture was put into 
the following PCR machine heat cycle: 1) 95°C for 5 minutes, 2) 94°C for 30 
seconds, 3) 52°C for 30 seconds, 4) 72°C for 90 seconds, 5) repeat steps 2-4 
30 times, 6) 72°C for 10 minutes, 7) cooled at 4°C. 
Following the second PCR, 5 volumes PB (from a QIAgen Plasmid DNA Miniprep 
Kit) was added to the mixture, and the PCR product was cleaned by following 
the QIAgen Gel Extraction kit protocol. Final PCR product DNA was eluted in 
30 µL double distilled H2O and sent for sequencing with the primer KAN4. 
2.20.  in vitro integrase reactions 
In vitro recombination assays were set up in microcentrifuge tubes as follows: 
21 µL IRB3 buffer, 8 µL plasmid substrate, 5 µL integrase enzyme at 8 µM were 
added to a single tube. For integrase-RDF reactions, a 2.5 µL sample of each 
component at 8 µM concentration were mixed together (for final 
concentrations of 4 µM integrase and 4 µM RDF) and incubated at room 
temperature for 15 minutes prior to addition of buffer and substrate. The 
sample was then vortexed and incubated in a 30°C water bath for 30 minutes 
before stopping the reaction by heating in a 80°C heat block for 5 mins 
followed by cooling on ice for 5 mins. Added to this was 25.5 µL B103 buffer 
and 49.5 µL NruI. The sample was then incubate at 37°C for 1 hour. Following 
this incubation, 15 µL of an SDS / protease K / EDTA mix was added and 
incubated for another 15 mins at 37°C. Samples were then run in an agarose 
gel electrophoresis and visualised by UV. 
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2.21. in vivo galK recombination assay 
In vivo recombination activity was tested using the galK MacConkey assay. E. 
coli cells containing an integrase expression plasmid (either continuous or 
arabinose-induced; see plasmids in Methods Section 2.5) were chemically 
transformed with the galK attP/attB substrate plasmid pGD001 (Methods 
Section 2.5), with transformants selected on MacConkey agar plates (Methods 
Section 2.2) containing kanamycin (pGD001 backbone) and an appropriate 
antibiotic to select for the expression plasmid. If recombination has taken 
place across the pGD001 substrate, colonies appear yellow/white due to loss 
of the galK gene, but appear pink/red if sufficient recombination has not 
occurred (this is explained in more detail in Chapter 3).  
After photographing plates, cells were ‘scraped’ from the agar by adding 1 mL 
of LB and pulling an ethanol-sterilised glass spreading rod across the plate to 
dislodge cells. Plasmid DNA was then extracted from these cells using a 
QIAgen Plasmid DNA Miniprep Kit, and the resulting DNA sample was run in an 
agarose gel. 
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2.22.  Yeast lithium acetate transformations 
Yeast KanMX knockouts were first streaked from glycerol stocks onto YPD and 
incubated for 2 days at 30°C. From single colonies, overnight cultures of 10 
mL YPD liquid media were set up at a temperature of 30°C with shaking at 
200 rpm. After incubation for 15 hours, the OD600 of each was recorded at 0.4 
- 0.5, equivalent to 5 x 106 cells per mL. From these cultures, 2 mL was 
inoculated by sterile pipetting into conical flasks containing 50 mL YPD media. 
The 50 mL cultures were then incubated at 30°C, shaking 200 rpm, for 3-4 
hours until an OD600 of 0.1 - 0.2 was achieved, roughly equivalent to 2 x 106 
cells per mL. The following lithium acetate  transformation method was based 
on the high efficiency yeast transformation protocol published by Pan et al. 
(2007). Each 50 mL, 4-hour culture was harvested by centrifugation at 5,000 
rpm for 2 minutes at room temperature, then washed once in 10 mL of sterile 
water. Cells were then washed again with 10 mL of 0.1 M lithium acetate, 
prepared fresh in buffer TE (pH 8.0). Pellet was gently resuspended in residual 
lithium acetate to a total volume of 300 µL, enough for 3 reactions. For each 
transformation reaction, 100 µL of this cell suspension was transferred to a 
fresh 1.5 mL microcentrifuge tube, kept on ice.  
A transformation mixture was prepared fresh for each reaction as follows: 480 
µL 50% polyethylene glycol (PEG-3350, Sigma) in buffer TE (pH 8.0), 72 µL 1M 
lithium acetate, 40 µL denatured salmon sperm carrier DNA (ssDNA) at 10 mg/
mL (ssDNA placed in a heat block at 100°C from frozen for 5 minutes, then 
immediately cooled on ice prior to use), 20 µL DNA (~1 µg per reaction) and 
buffer TE (pH 8.0) to volume.  
620 µL of the transformation mixture was added to each 100 µL 0.1M lithium 
acetate cell suspension and mixed thoroughly by pipetting only. The reaction 
was then incubated at 30°C for 30 minutes in a water bath before adding 72 
µL dimethyl sulfoxide (DMSO) and mixed thoroughly by pipette. Cells were 
then heat shocked at 42°C for 15 minutes in a water bath, then harvested by 
centrifugation at 3,600 rpm for 30 seconds. Cells were resuspended in 400 µL 
5mM CaCl2 and incubated at room temperature for 10 minutes. Following this, 
 71
cells were spun down at 3,600 rpm for 30 seconds and resuspended in 1 mL 
YPD liquid media. Microcentrifuge tubes containing the resuspended cells 
were then placed horizontally in a 30°C incubator shaking at 200 rpm for 2.5 
hours, the harvested by centrifugation at 3,000 rpm for 2 minutes. Pelleted 
cells were finally resuspended in 200 µL YPD liquid media and plated onto SD-
uracil agar plates for URA selection using a sterilised glass rod. Transformation 
plates were incubated at 30°C for 2 - 3 days. 
2.23.  DNA quantification from agarose gels (digital) 
To roughly quantify the relative concentrations of DNA bands in agarose gels 
from recombination assays, the software ImageJ (developed by the National 
Institutes of Health) was used to analyse gel photographs. Firstly, gel images 
were black-white inverted. In ImageJ, rectangular areas were selected at the 
four expected band locations in each column on the gel. Each column (i.e. 
each recombination assay reaction) was analysed individually. From these four 
areas, ImageJ measures the relative pixel concentrations in each band, first 
plotting the data as peaks. Each peak was isolated from the next using the 
line drawing tool. ImageJ then calculates the relative intensity/area of each 
peak could as a percentage. The percentage of substrate DNA that had been 
recombined or unrecombined could then be calculated by adding together the 
two recombined product bands and the two unrecombined bands. See Chapter 
5 for more details. 
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3.  Chapter 3: Demonstrating an integrase 
‘landing pad’ (LP) in E. coli 
3.1.   Introduction 
The integrase landing pad (LP) system on which this project focuses has been 
designed to facilitate integration of a target gene into E. coli or other 
microbial genomes with maximum efficiency and accuracy. The LP cassette 
consists of a marker gene flanked by two attB sites in a head-to-head 
orientation. In this set-up, the two attB sequences differ by their central 
dinucleotide pairings, making use of the requirement for matching 
attachment sites described previously in Chapter 1. This feature ensures that 
a ‘donor’ cassette, consisting of a target gene flanked by the corresponding 
attP sites in a head-to-head orientation, is integrated in the desired 
orientation and at high efficiency due to site-directed cassette exchange.  
An early study which demonstrated how attachment sites on the genome 
could be used for heterologous gene integration was done by Bierman et al 
(1992), who site-specifically integrated heterologous plasmid DNA containing a 
single attP site into the φC31 native host Streptomyces. Single attachment 
sites have also been inserted, or natural pseudo-sites discovered, in 
eukaryotic cells which allow integrations of plasmid DNA through a single attB 
x attP site recombination reaction (Thyagarajan et al., 2001). However, the 
LP system described here marks an improvement on these previous methods 
as it allows for integration of a gene at a chosen location, wherever an LP 
sequence is introduced, and requires only one integration event to place the 
target gene on the genome, without the need for consequent excision of a 
plasmid backbone. The efficiency and accuracy of the LP system is also 
expected to be higher than previous single-site methods as it requires the 
site-specific recombination of two differing attB-attP pairings in the correct 
orientation, reducing the likelihood of off-target integration events.  
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The initial target of this project was to demonstrate a landing pad with sites 
for φC31 integrase on the E. coli genome. φC31 integrase has been well 
characterised by this lab and has been demonstrated to work efficiently in E. 
coli without detriment to cell growth. 
This section of the project aims to establish a φC31 integrase LP in a chosen 
location on the E. coli genome via an intermediate recombineering step, and 
demonstrate φC31 integrase-mediated cassette exchange at this site. 
Cassette exchange experiments were designed to measure efficiency of 
exchange using loss and gain of antibiotic resistance markers. When a marker 
on the genomic LP site is lost and a donor cassette marker is gained in a 
successful cassette exchange, this can be tested in the resulting colonies by 
checking for antibiotic resistance or sensitivity to the associated antibiotics. 
A significant challenge was to come up with a way to deliver the donor 
cassette while still allowing consequent selection of the antibiotic resistance 
markers. Plasmid delivery is the most stable and effective method of delivery 
of the donor cassette. However, as plasmids remain in the cells after 
transformation, presence of the donor marker (and plasmid backbone marker) 
poses a problem for selection screening. The plasmid used must therefore be 
removed from the cells before checking for antibiotic resistances of the LP 
and donor cassettes.  
The ideal delivery method for this system is the transformation of a simple 
PCR product, as discussed previously. While this would avoid the issue of 
marker incompatibility and unwanted persistence in the cells, linear DNA 
suffers from problems of instability in E. coli cells due to action of native 
endonucleases. Alongside these challenges, an high efficiency cassette 
exchange protocol must also be optimised for simultaneous donor delivery and 
integrase expression and activity. 
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3.2.  Design and construction of a φC31 integrase 
landing pad 
3.2.1.  Design of the φC31 LP construct 
For the first landing pad design of this project, two attB sites for φC31 
integrase were arranged in a head-to-head orientation around the antibiotic 
resistance marker for erythromycin, EmR. An overview diagram of this initial 
φC31 integrase landing pad is shown in Figure 3.1. The first attB site features 
a TT central dinucleotide pair and the second attB site features a TC central 
dinucleotide pair; these att sites are shown in Figure 3.2. The sequences, 
which are smaller than the complete φC31 integrase att site sequences found 
naturally, were chosen to be shorter where possible while still maintaining the 
highest possible level of recombination efficiencies. The sites selected (a 46 
bp attB site and 50 bp attP site) are based on a previous study (Groth et al., 
2000) which showed that reducing the length of a natural attB site (60 bp 
from Streptomyces lividans) to 35 bp in length had no effect on recombination 
efficiency, while reducing the natural φC31 integrase attP site (60 bp) to 
46-50 bp in length also produced recombination efficiencies equal to that of 
the full sites. The central dinucleotide pairs of TT (which is unchanged from 
the natural φC31 integrase att sites), and TC were chosen due to observations 
in this lab that altering the TT to a TC does not have an effect on 
recombination efficiency, and that these sites have been shown to recombine 
exclusively with their matching central dinucleotide counterpart site. 
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Figure 3.1: Initial φC31 integrase landing pad design consisting of an 
erythromycin resistance marker flanked by attachment sites attBTT and 
attBTC. Sequences of the attB sites in this design are shown in Figure 3.2. 
Figure 3.2 : Sequences of φC31 integrase attB and attP sites used in 
the φC31 landing pad (see  Figure 3.1) and donor cassettes (see 
Figure 3.6), with alternate central dinucleotide pairings TT and TC.
3.2.2.  Insertion of the LP cassette into the E. coli gene pepA by 
λ Red recombineering 
The location for this initial genomic landing pad was selected as the non-
essential E. coli pepA gene, due to it having been previously mutated without 
negative impact to the cell (Reijns et al., 2005) and the availability of a pepA 
knockout assay. The pepA gene encodes an aminopeptidase, which has a role 
as an accessory protein in the XerC/XerD recombinase dimer resolution 
mechanism (Reijns et al., 2005). 
The φC31 integrase landing pad was inserted into the pepA locus, replacing 
the entire gene, via the λ Red recombineering method. This is a method of 
facilitating integration of a PCR product into the genome via homologous 
recombination. The desired sequence to be integrated is amplified by PCR 
with flanking regions of homology to the targeted gene. The PCR product is 
then introduced into E. coli cells expressing the λ Red proteins, which block 
activity of cellular endonucleases and promote homologous recombination. A 
diagram illustrating how this mechanism acts to replace the pepA gene with a 
homology-added φC31 integrase LP (EmR) PCR product is shown in Figure 3.3.  
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E. coli DS941 cells were transformed with λ Red recombineering plasmid 
pKOBEG-A (Chaveroche et al., 2000), expressing λ Red proteins (Gam, a 
nuclease inhibitor; Exo, a 5’ to 3’ exonuclease; and Beta, which protects and 
promotes annealing to the ssDNA created by Exo) under control of the pBAD 
promoter which is induced by the addition of arabinose. Successful 
transformants were isolated by selecting for ampicillin resistance carried by 
the pKOBEG-A vector. This plasmid is designed to be temperature-sensitive in 
order to allow removal following successful recombineering; this occurs due to 
the presence of a mutation in the pSC101 origin backbone which prevents 
replication of the plasmid at temperatures above 37°C (Hashimoto-Gotohi & 
Sekiguchi, 1977). Therefore all growth steps consequent to transformation 
were conducted at 30°C in order to maintain the pKOBEG-A plasmid in the 
cells. These DS941 cells containing pKOBEG-A were then ready for induction of 
Red functions and transformation with the LP recombineering PCR product. 
Primers were designed to amplify the EmR gene with φC31 integrase attBTT 
and attBTC sites flanking up- and downstream respectively, along with 50 bp 
homology sequences to the start and end of the pepA gene. These primer 
sequences are shown in Methods Section 2.4. Using these primers, the 
recombineering cassette (LPC31) was amplified using a Phusion polymerase 
protocol nicknamed ‘Phussean' (Methods Section 2.13.), which has been 
optimised for performance with larger primers such as the oligonucleotide 
primers synthesised for this PCR (123 bp forward primer, 129 bp reverse 
primer; see Methods Section 2.4). The PCR template used was the EmR gene 
found on the genome of the E. coli DS941-derived strain π1 (see Methods 
Section 2.5), a strain previously engineered by this lab, in a method that 
allows amplification directly from the genome by resuspending a colony in 
water and adding it to the reaction set up (Methods Section 2.13.) 
Purification of the PCR product was done in one of two ways during 
recombineering experiments.  
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At first, PCR reactions were directly run in their entirety on a 1% agarose gel 
and the correctly sized DNA band (1253 bp) was excised and extracted using a 
QIAgen Gel Extraction kit. However, after several unsuccessful attempts at 
recombineering with this PCR product sample, it was thought that exposure to 
UV during excision of the agarose gel band was having a damaging effect on 
the DNA, thus decreasing efficiency of the homologous recombineering 
process. Subsequent PCR products of the LP recombineering fragments were 
purified using a QIAgen PCR Purification kit immediately after completion of 
the PCR, and a sample of this eluted DNA was run on a 1% agarose gel to 
confirm the presence and size of the DNA. This avoided damage to the DNA by 
UV radiation and increased chances of successful recombineering in 
subsequent protocols. 
The φC31 LP recombineering PCR product was introduced by electroporation 
into DS941/pKOBEG-A cells that had been induced by L-arabinose for λ Red 
functions. Following transformation and recovery at 30°C, successful EmR LP 
recombinants were selected by their resistance to erythromycin. Initially the 
efficiency of recombineering was seen to be very low, with many repetitions 
of the protocol resulting in no observed EmR-positive colonies on 
erythromycin LB agar plates.  
After many iterations of this method, when successful erythromycin-resistant 
colonies were finally seen (healthy colonies on LB + erythromycin plates 
following electrotransformation) colony counts were very low, with a 
maximum of 4 colonies per plate observed. It should be noted that of these 
successful plates, it was found that incubating agar plates at 37°C rather than 
30°C resulted in an improved rate of recombineering. This had previously 
been suggested to be an improved temperature for the activity of the λ Red 
proteins, and while the higher temperature decreases the ability of pKOBEG-A 
to proliferate, sufficient expression of the λ Red proteins should be  
completed at this stage and maintenance of the plasmid is not essential. 
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In order to clear transformed cells of the pKOBEG-A temperature-sensitive 
plasmid, erythromycin-resistant colonies were streaked onto LB agar plates 
plus erythromycin and grown at 42°C. At this temperature, replication of the 
pKOBEG-A plasmid is inhibited and the vector does not proliferate. After 
several generations the temperature-sensitive plasmids should therefore 
eventually be lost from the cells. After two rounds of re-streaking and growth 
at 42°C, cells were tested for loss of the pKOBEG-A plasmid by streaking onto 
LB agar plus ampicillin. Absence of growth on these plates indicated the 
successful loss of the plasmid.  
3.2.3.  Confirmation of LP insertion by PCR 
To confirm insertion of the φC31 LP cassette into the pepA locus, PCRs were 
designed to read across the flanks of the LP and into the upstream and 
downstream genes flanking the pepA gene. PCR primers were designed to 
anneal to 20-bp sequences upstream and downstream of pepA, in the genes 
yjgP and holC, respectively. Forward and reverse primers were also designed 
to anneal in both the pepA gene and EmR gene, to be used to test for 
presence of either gene in the LP location; the former indicating unsuccessful 
recombineering, the latter indicating successful integration of the φC31 LP 
cassette. A list of these primer sequences can be seen in Methods Section 2.4.  
A diagram representing the five confirmatory PCRs is shown in Figure 3.4. For 
these reactions, E. coli DS941 was used as a negative control. In the case of 
successful integration of the φC31 LP cassette, PCR1 (upstream to 
downstream pepA), PCR4 (upstream to EmR) and PCR5 (EmR to downstream) 
should amplify. In the case of no pepA replacement, PCR1, PCR2 (upstream to 
pepA) and PCR3 (pepA to downstream) should amplify. PCR1, which amplifies 
across the whole pepA site, should produce a differently sized band 
dependent on whether the LP integration is successful or unsuccessful, as 
indicated in the product size table of Figure 3.4.  
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These five confirmatory PCRs were performed on a selected erythromycin-
resistant colony,  obtained from a recombineering transformation, alongside 
DS941 as a negative control. Figure 3.5 shows these PCRs run on a 1% agarose 
gel with a 1 kb marker ladder. According to the expected band sizes, the 
erythromycin-resistant recombineering transformant, from here on labelled as 
LPC311a, is positive for pepA replacement with LPC31. Particularly convincing 
is the amplification of PCR4 and PCR5, which show amplification from the 
EmR gene to the flanking regions of pepA. In addition, PCR2 shows 
amplification of the different expected bands from the original DS941 and 
LPC311a, with no amplification of pepA in the latter, suggesting complete 
replacement by recombineering. Strain LPC311a was grown overnight in LB 
liquid culture and a glycerol stock was created to preserve the successful LP 
strain for future use. 
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 3.3.  Development of an appropriate method for 
cassette delivery 
3.3.1.  Designing a temperature-sensitive donor vector 
The initial ‘donor’ cassettes to be integrated into LPC31 consisted of an 
antibiotic resistance marker for either chloramphenicol (CmR) or kanamycin 
(KmR) flanked by the attPTT and attPTC sites which correspond to the LPC31 
attB sites. These donor cassettes, when transformed into LPC311 cells 
expressing φC31 integrase, were designed to recombine with their 
corresponding attB sites resulting in cassette exchange across the LP, 
replacing the EmR gene with CmR or KmR. A diagram showing these donor 
cassette designs and the recombination reactions by which cassette exchange 
occurs across the LP is shown in Figure 3.6. 
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To begin with, donor cassettes were to be delivered via a plasmid vector. A 
desirable aim of the LP system is to eventually be able to transform the donor 
cassette as a PCR product. However, using a plasmid vector first would allow 
for stable transformation of the cassette and for LP integration to be 
demonstrated before attempts with linear DNA (which faces the problem of 
degradation by native E. coli endonucleases following transformation).  
Using a plasmid vector for donor cassette delivery presented the problem of 
marker detection following cassette exchange, as the donor plasmid, which 
contains the marker before integration, can also express the antibiotic 
resistance gene (for chloramphenicol or kanamycin). The solution to this was 
to use a temperature-sensitive plasmid vector, which could be removed from 
cells following cassette exchange by growing transformants at a higher 
temperature. Once cells are cleared of the donor plasmid they can be tested 
for resistance to the donor marker antibiotic to confirm cassette exchange 
into the genome. 
The temperature-sensitive vector chosen was based on the plasmids used for λ 
Red recombineering transformations, pKOBEG-A (ApR backbone), or 
alternatively pKOBEG-C (CmR backbone) (Chaveroche et al., 2000). This 
plasmid contains the repA101ts gene which encodes the protein RepA101ts, 
and the pSC101 origin of replication. RepA101ts binds to the origin to initiate 
replication at a temperature of 30°C, but becomes inactive at temperatures 
between 37°C and 42°C (Hashimoto-Gotohi & Sekiguchi, 1977). Therefore, 
when cells containing the temperature-sensitive plasmid are grown at 42°C, 
the plasmid is no longer able to replicate and is lost. This function is ideal for 
temporary delivery of the donor cassette. 
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Donor cassettes for CmR and KmR, as shown in Figure 3.6, were produced via 
PCR using primers containing the desired attP sequences that amplified the 
chloramphenicol resistance gene (cat) and kanamycin resistance gene (aph) 
from the template plasmids pSW23 and pSW29 (Demarre et al, 2005), 
respectively. Included were restriction endonuclease sites for HindIII (forward 
attPTT) and KpnI (reverse attPTC) for cloning into pKOBEG-A or pKOBEG-C, 
replacing completely the λ Red protein genes and pBAD promoter. These 
primers can be seen in Methods Section 2.4.   
Initial cassette vector cloning yielded three combinations of donor marker and 
vector backbone resistance genes as follows: pRM1 (CmR donor, ApR 
backbone), pRM2 (KmR donor, CmR backbone), pRM3 (KmR donor, ApR 
backbone). These plasmids are shown in Methods Section 2.5.  
3.3.2.  Development of the φC31 LP cassette exchange protocol 
(temperature-sensitive donor plasmid) 
φC31 LP cassette exchange transformations were based primarily on 
transformations used for recombineering. This used a protocol for high 
efficiency transformation of electrocompetent cells, and using a similar 
method to recombineering has the added advantage of providing a comparison 
of efficiency between the homologous recombination approach and the use of 
serine integrase enzymes.  
φC31 integrase was first expressed constitutively in cells from the plasmid 
pFEM32, which carries ampicillin resistance (Methods Section 2.5). pFEM32 
was introduced into LPC311a cells first by chemical transformation. LPC311a/
pFEM32 cells were subsequently transformed with pRM2 (KmR donor, CmR 
backbone) by LP cassette exchange electrotransformation (see Methods 
Section 2.17). Following recovery, successful transformants were selected on 
LB agar plates containing kanamycin at 30°C. At this temperature, pRM2 
should be maintained inside the LPC311a cells. 
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In order to then clear LPC311a cells of pRM2 and measure for cassette 
exchange, 100 colonies were taken from LB-kanamycin transformation plates 
and patched by toothpick onto another LB agar plates with no antibiotic. 
These 100-grid plates were then incubated at 42°C overnight. This process 
was repeated the next day onto another 100-grid LB agar plate (no 
antibiotics) to be incubated at 42°C for a second overnight growth. The 
reason for not including kanamycin in these LB plates at this stage was to 
avoid selecting for any remaining pRM2 expressing the KmR gene while in the 
process of trying to remove the plasmid from the cells by heating. This had 
been a problem in initial cassette exchange experiments, where selecting  for 
cassette integration by kanamycin resistance seemed to override the 
temperature-based removal of the donor plasmid due to the backbone also 
carrying the KmR gene. 
After two 42°C overnight incubations, each of the 100 transformant patches 
were transferred from the LB plates containing no antibiotics to three 100-
grid LB plates containing either erythromycin (to test for remaining un-
replaced EmR LP), chloramphenicol (to test whether cells had been 
successfully cleared of pRM2) or kanamycin (to test for successful cassette 
exchange in the case that pRM2 had been removed from the cells). 
In each set of 100 transformants tested across these plates, it was found that 
cells were still erythromycin resistant but had lost the pRM2 plasmid, with 
each patch growing on LB plus erythromycin but not on LB plus kanamycin, 
indicating that cassette exchange had been unsuccessful and the erythromycin 
resistance gene remained in place at the LP site. This suggests that cassette 
exchange has been unsuccessful in all pRM2 transformants and there appeared 
to be an issue with the cassette exchange protocol or the LP cassette 
sequence. 
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3.4.  Addressing problems with φC31 integrase 
expression in the LP strain LPC311 
3.4.1.  Measuring φC31 integrase activity by the GalK 
recombination assay 
To determine the cause of the unsuccessful cassette exchange, the activity of 
φC31 integrase in the LPC311a cells was investigated. This was done using a 
GalK recombination (MacConkey) assay. The assay is an in vivo test for 
recombinase activity, which uses a substrate plasmid containing attB and attP 
sites in a head-to-tail orientation around a reporter gene encoding 
galactokinase, galK, which is required for the metabolism of galactose.  
When cells containing the complete substrate expressing galK are grown on 
plates of MacConkey agar containing galactose as the only carbon source and 
a pH indicator (2-methyl-3-amino-6-dimethylaminophenazine) which shows 
red at pH < 6.8 and yellow at pH > 8.0, colonies appear red or pink. If 
recombination occurs between attB and attP, the galK gene is lost and cells 
are unable to metabolise galactose, forcing them to metabolise amino acids in 
the MacConkey agar, raising the pH and resulting in the formation of white 
colonies.  
Following visual confirmation of red or white colony formation on MacConkey 
agar, further confirmation of recombination can be observed by extracting the 
plasmid DNA from the cells. This plasmid DNA is then cut with a restriction 
endonuclease (NruI, for which there are two sites on the substrate plasmid), 
then running the resulting DNA on an agarose gel to check the size of the 
fragments. An illustration of this assay and the sizes expected for substrate 
pGD001 are shown in Figure 3.7.  
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 Figure 3.7: Diagram illustrating MacConkey recombination assay used to 
measure φC31 integrase activity in DS941 and LPC311a cells. When the 
substrate plasmid, pGD001 (see Methods 2.5), is introduced by 
electrotransformation into E. coli cells expressing φC31 integrase, 
recombination should occur between attachment sites attP and attB, resulting 
in the excision of a DNA fragment containing the galK gene and the formation 
of two plasmids, the larger of which consists of the plasmid backbone 
containing the origin of replication and a smaller plasmid containing galK but 
no origin; the new smaller galK-containing plasmid is therefore lost from the 
cells due to its lack of an origin, while the larger plasmid is maintained by 
selecting for kanamycin resistance. When cut with restriction endonuclease 
NruI, the substrate produces two fragments of sizes 933 bp and 4248 bp, while 
recombined plasmid produces a single 3270 bp fragment. 
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DS941 and LPC311a cells containing pFEM32 (which constitutively expresses 
φC31 integrase) were transformed via a standard electroporation protocol 
with the φC31 attB-attP galK substrate plasmid pGD001. DS941 and LPC311a 
cells containing pFEM35 (constitutive expression of Bxb1 integrase) were also 
transformed as a recombination-negative control. Recovered cells were then 
spread on MacConkey agar plates containing galactose and kanamycin (pFEM32 
and pFEM35 vector selection) and incubated overnight at 37°C. Photographs of 
these plates are shown in Figure 3.8. 
MacConkey transformation plates were then scraped (1 mL liquid LB added 
and plate swept with a sterile glass rod to dislodge cells from colonies) to 
collect as many cells as possible. The plasmid DNA was then extracted with a 
QIAgen Plasmid DNA Miniprep Kit and digested with NruI to be run on an 
agarose gel. This agarose gel is shown in Figure 3.9. 
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 Figure 3.8: GalK assay MacConkey plates showing transformations of substrate 
plasmid pGD001: A) DS941/pFEM32 expressing φC31 integrase, B) DS941/
pFEM35 expressing Bxb1 integrase, C) LPC311a/pFEM32 expressing φC31 
integrase, D) LPC311a/pFEM35 expressing Bxb1 integrase. The high 
percentage of white or cream coloured colonies seen in A) indicate efficient 
recombination. By comparison, a much lower number of white colonies are 
seen in C), suggesting that φC31 integrase recombination activity is much 
lower in LPC311a/pFEM32 cells compared to DS941/pFEM32 cells. 
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In Figure 3.9, DS941 cells expressing φC31 integrase show almost complete 
recombination of the pGD001 substrate, producing a strong band of 3270 bp in 
length. In contrast, and in line with results observed from MacConkey plates, 
LPC311a cells expressing φC31 integrase show very little recombination, 
leaving strong bands of unrecombined pGD001 (cut with NruI) of lengths 4248 
bp and 933 bp. Unexpected bands were also observed in this DNA sample. The 
appearance of these bands, indicated in Figure 3.9 by purple circles, appears 
to be in balance with the disappearance of the pFEM32 band in this sample 
(the highest band in this lane).  
3.4.2.  Determining the fate of the φC31 integrase expression 
plasmid in LPC311a cells 
After detecting unexpected bands in the LPC311a galK assay DNA samples, 
suspected to be connected to the loss of φC31 integrase expression plasmid 
pFEM32 as seen in the agarose gel shown in Figure 3.9, the next step was to 
investigate what was happening to this plasmid during φC31 integrase 
expression in LPC311a cells. The unexpected DNA bands were not seen in 
DS941 cells, which do not feature the inserted φC31 LP cassette containing 
two attB sites, indicating that these sites may be having an effect on the 
expression plasmid and possibly the health of the E. coli cells. 
To begin investigating the effect of continuous φC31 integrase expression 
from the pFEM32 plasmid in LPC311a cells, DS941 and LPC311a glycerol stocks 
containing either pFEM32 or pFEM35 (Bxb1 integrase) were streaked onto LB 
agar plates containing ampicillin to select for the ApR-carrying plasmids, and 
erythromycin for LPC311a only to select for the LP EmR marker. It was 
observed that LPC311a cells containing pFEM32 (expressing φC31 integrase) 
grew far less on these agar plates than LPC311a cells containing pFEM35, or 
DS941 cells containing either plasmid. Photographs of these plates are shown 
in Figure 3.10.  
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 Figure 3.10: E. coli cells containing constitutive expression plasmids for φC31 
integrase (pFEM32) and Bxb1 integrase (pFEM35) control: A) DS941+pFEM32, B) 
DS941+pFEM35, C) LPC311a+pFEM32, D) LPC311a+pFEM35. Note the poor 
growth of LPC311a cells expressing φC31 integrase on plate C. Cells are 
streaked onto LB agar containing ampicillin to select for the ApR-carrying 
expression plasmid (A, B, C & D) and erythromycin to select for EmR on the 
LPC311 genome (C & D only). 
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While this could be seen as a possible indication that φC31 integrase 
expression inhibits growth of LPC311a cells, it is also important to note that 
because these streaks were taken by toothpick from a glycerol stock, the 
number of cells streaked onto the plates pictured could have been 
inconsistent between the plates. Nonetheless, it was a consistent observation 
that LPC311a/pFEM32 cells grew less on ampicillin and erythromycin plates, 
as also seen in the low colony count of LPC311a/pFEM32 MacConkey assay 
plates in Figure 3.8. 
To find out what was happening to the pFEM32 plasmid in LPC311a cells, 
several single colonies were taken and grown overnight in liquid LB media plus 
ampicillin and erythromycin. Additionally, a single colony of DS941/pFEM32 
was also selected and grown overnight with ampicillin selection. Plasmid DNA 
was then extracted from these overnight cultures (using a QIAgen Plasmid DNA 
Miniprep Kit), and this DNA was run on an agarose gel. Figure 3.11 shows an 
agarose gel of pFEM32 extracted from DS941 and five LPC311a colonies. In the 
agarose gel shown here, the DNA is uncut and therefore the brightest bands 
observed are supercoiled DNA, with an above fainter nicked DNA band (better 
indicating the size of the plasmid). 
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 Figure 3.11: pFEM32 extracted from DS941 cells and 5 single LPC311a 
colonies, A-E, run on a 1% agarose gel by electrophoresis. NEB 1kb ladder 
included for size reference. 
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In LPC311a, pFEM32 appears to be converted to two different fragments of 
DNA at sizes ~ 5 kbp and ~ 2.2 kbp. In each of these five colonies, the plasmid 
appears to have been completely converted to either one or both of these 
plasmids. It can be assumed that these products are replicating plasmids and 
still contain the origin of replication and selection marker as they were 
maintained in vivo, and would have been lost if linear. In contrast, as 
previously indicated, pFEM32 is stable in DS941 and there is no conversion to 
these products. 
The cause of this plasmid instability could be due to an interaction between 
φC31 integrase and the LP attB sites. One possibility is that due to constant 
expression (and possible build-up) of integrase, the enzyme might be 
recombining one of these LP sites with a pseudo-attP site in the E. coli 
genome, with a negative effect on the viability of the cells. This would 
explain the poor growth of LPC311a + pFEM32 on agar plates. In these cells, 
the reaction against the negative events caused by φC31 integrase activity 
appears to be deletion of the expression plasmid, acting as a counter-
selection against φC31 integrase and resulting in poor recombination activity 
within the cells. For the continuation of this project it was therefore clear 
that constitutive expression of φC31 integrase in LPC311a cells causes genetic 
instability, and an alternative expression solution must be implemented.  
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3.4.3.  An inducible φC31 integrase expression method for 
improved activity in LPC311a 
To overcome the problems observed with continuous expression of φC31 
integrase, a decision was made to regulate φC31 integrase expression more 
tightly using an inducible promoter. A plasmid vector which expresses φC31 
integrase under control of the arabinose-inducible pBAD promoter complex, 
pZJ7, had already been cloned and used in this lab (Methods Section 2.5). The 
pBAD promoter is induced by addition of L-arabinose and inhibited by the 
addition of glucose (Guzman et al., 1995). 
The  pZJ7 φC31 integrase inducible expression plasmid (CmR) was introduced 
into DS941 and LPC311a cells by chemical transformation (Methods Section 
2.9.1), with transformants selected by chloramphenicol resistance. In vivo 
recombination assay transformations with the GalK attP-attB substrate 
pGD001 were repeated as previously (Methods Section 2.21) with two 
alterations. Firstly, in order to suppress expression of φC31 integrase, glucose 
was added to the overnight starter cultures before inoculation into larger 
cultures for making electrocompetent cells. Secondly, arabinose was added to 
induce φC31 integrase expression under control of the pBAD promoter half 
way through growth of electrocompetent cell cultures (~1.5 hours uninduced 
growth followed by ~1.5 hours induction). A control culture was also set up 
containing glucose throughout growth in order to suppress expression of φC31 
integrase. Cells recovered after electroporation were spread onto MacConkey 
plates containing galactose and kanamycin (selecting for pGD001). 
Photographs of these plates are shown in Figure 3.12.  
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To confirm whether inducible φC31 integrase expression leads to more 
efficient recombination in LPC311a cells compared to previous constitutive 
expression, MacConkey plates were scraped and pGD001 DNA was extracted. 
This DNA was then run, non-linearised, on an agarose gel. This gel is shown in 
Figure 3.13, where a clear band of recombined pGD001 (3270 bp, supercoiled) 
can be seen only in pZJ7-containing cells induced with arabinose (lane ‘ara 
+’). While there is still a strong band of unrecombined pGD001, indicating 
incomplete recombination, this is still a significant level of recombination and 
is in sharp contrast to cells with glucose suppression rather than arabinose 
induction (lane ‘ara -, gluc +’), where no recombination product can be seen.  
 
Figure 3.12: MacConkey agar plates from GalK recombination assay pGD001 
transformations into a) LPC311a cells containing arabinose-induced pZJ7 
(therefore expressing φC31 integrase) and b) LPC311a cells containing pZJ7 
suppressed by addition of glucose. Complete recombination is indicated by 
presence of only yellow/pale-coloured colonies in the arabinose-induced cells 
(a). In contrast, the glucose-suppressed cells (b) only give red colonies, 
indicating incomplete (or zero) recombination between attB and attP. 
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Figure 3.13: Agarose gel showing DNA extracted from MacConkey plates of 
LPC311a cells containing pZJ7, transformed with pGD001 after being grown 
under two conditions: 1) ara+, 3-hour induction with 10% L-arabinose; 2) ara- 
gluc+, no arabinose induction, but with the addition of 10% glucose to 
suppress φC31 integrase expression. pGD001 (5181 bp) and pZJ7 (7175 bp) 
plasmids are run alongside as a reference. The expected recombination 
product is a 3270 bp plasmid, indicated here with a green arrow. Due to the 
circular supercoiled nature of this plasmid (samples were not linearised with 
NruI following extraction), the recombination product size does not match 
size references of the linear reference ladder, which is shown for 
comparison.
3.5.  Optimisation of φC31 integrase LP cassette 
exchange protocol 
3.5.1.  Transformation of donor cassette delivery vector into 
LPC311 cells with induced φC31 integrase expression 
With φC31 integrase expression controlled in LPC311a cells by the arabinose-
inducible pBAD promoter on plasmid vector pZJ7, LP cassette exchange 
experiments were repeated. LPC311a cells that had first been transformed 
with pZJ7 were then transformed with the temperature-sensitive KmR LP 
donor plasmid pRM3 (Methods Section 2.5). This was done by following the 
previously used high efficiency electrotransformation protocol for 
recombineering in which arabinose was added for induction prior to cell 
cultures reaching log growth phase (Methods Section 2.15). Cells recovered 
after electroporation were plated onto LB agar containing chloramphenicol, 
selecting for the backbone of pRM3. Selecting for the backbone rather than 
the donor cassette means that the number of successful plasmid 
transformants could then be counted. The percentage of these transformants 
that had successfully performed cassette exchange could then be calculated 
by testing large numbers of colonies for loss of erythromycin resistance and 
gain of kanamycin resistance once the cells had been cleared of pRM3 by 
heating at 42°C. Cassette exchange could then be confirmed beyond doubt 
using PCRs that read across the att site junctions and DNA sequencing of the 
PCR products. 
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3.5.2.  Detection of cassette exchange 
3.5.2.1.  Antibiotic-resistance markers 
Following transformation of induced LPC311a/pZJ7 cells with KmR donor 
plasmid pRM3, colony counts on the LB agar recovery plates containing 
chloramphenicol averaged around 1000 colonies (Methods Section 2.17). 100 
of these single colonies were taken and patched onto a 100-grid LB agar plate 
containing no antibiotic, to be incubated overnight at 42°C. From this 
overnight plate, the patching process was repeated onto a second LB agar 
plate (no antibiotic) and again incubated at 42°C overnight (Methods Section 
2.16). Patches were then transferred by toothpick onto three different LB 
agar plates to test for resistance to three antibiotics: chloramphenicol to 
detect continued presence of CmR-carrying pRM3; kanamycin, which in 
combination with loss of CmR will indicate successful cassette exchange of 
KmR into the LP; and erythromycin to test for cassette exchange by loss or 
retention of the EmR LP marker gene. 
Initial antibiotic patch tests revealed that 100/100 colonies remained 
resistant to all three antibiotics. This was first thought to be an indicator that 
the temperature-sensitive pRM3 was not being removed from the cells by 
heating and thus preventing determination of whether cassette exchange was 
occurring. If the temperature-sensitive plasmid was indeed persisting in the 
cells, the observation of all three resistances could indicate one of two 
outcomes; either no cassette exchange occurs and pRM3 remains in the cells 
unchanged, or cassette exchange takes place leaving kanamycin resistance at 
the LP site on the genome, with the erythromycin resistance marker EmR 
taking its place on the temperature-sensitive vector plasmid.  
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Several iterations of the φC31 integrase cassette exchange transformation 
protocol were tested. Altered protocols featuring induction of φC31 integrase 
expression with arabinose at different times during growth were explored, as 
well as suppressing φC31 integrase expression with glucose until the moment 
of induction, but these all led to the same outcome as described above.  
Several methods of recovery and growth following transformation were tested 
to determine whether temperature had an effect on cassette exchange or 
temperature-sensitive plasmid behaviour. Firstly, liquid recovery cultures 
following transformations were tested at 30°C, 37°C or 42°C, as well as 
incubating post-transformation plates at 30°C, 37°C or 42°C, but no 
difference was seen in the outcome of the protocol; all transformants tested 
on 100-grid plates remained resistant to all three antibiotics, indicating that 
cassette exchange was not taking place successfully.  
Transformants (kanamycin-resistant colonies) were also subjected to multiple 
lengths and rounds of heat treatment at 42°C in order to make sure cells were 
cleared of the temperature-sensitive donor plasmid. When plasmid DNA was 
extracted from these cells, samples showed no presence of pRM3 or any other 
similarly sized plasmid. This led to the suspicion that something else was 
happening in the cells in order for them to remain resistant to kanamycin, 
chloramphenicol and erythromycin without containing the donor plasmid that 
carries KmR and CmR. After this, a series of PCR reactions was devised to 
determine if any recombination or integration was occurring at the φC31 
integrase LP site. 
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3.5.2.2.  PCR amplification of landing pad region 
After several attempts to show cassette exchange using gain and loss of 
antibiotic resistance markers, PCRs were designed to check whether cassette 
exchange had taken place at the φC31 integrase LP site in LPC311a. Similar to 
the PCRs used to confirm the integration of the φC31 LP into the pepA locus 
by recombineering (see Section 3.2.3, Figures 3.4 and 3.5), primers were 
designed to amplify a region from outside the LP and across the att site 
junctions.  
In initial cassette exchange experiments, temperature-sensitive donor plasmid 
pRM3 was used as the donor plasmid, which features CmR as the donor 
cassette marker and an ApR backbone. However in later experiments, pRM2 
(KmR donor, ApR backbone) was used to avoid antibiotic resistance marker 
incompatibility with the new pZJ7 expression plasmid, which also carried a 
CmR marker. pRM2 and pRM3 are detailed further in Methods Section 2.5.  
The possible outcomes of initial pRM3 cassette exchange experiments should 
be either: no integration occurs and EmR remains in place, or cassette 
exchange is successful leaving CmR in the LP site flanked by two attL sites. 
The outcomes of initial cassette exchange transformations in LPC311a with 
pRM2 as a donor were probed by designing a PCR with primers that read from 
outside pepA into CmR, and therefore only amplify if CmR has been 
successfully integrated into the LP. A diagram of this PCR is shown in Figure 
3.14, and primers used are listed in Methods Section 2.4.  
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The PCR shown in Figure 3.14, which amplifies a sequence from upstream of 
pepA to inside the CmR marker, was used initially to test transformants in 
large numbers. Figure 3.15 shows an agarose gel of 38 of the 76 ara-induced 
LPC311a / pZJ7 + pRM2 transformants checked by this PCR. 100% of these 
transformants (76/76) showed a clear band of amplified DNA at the expected 
position (747 bp), indicating that CmR had been integrated into the LP at a 
high efficiency.  
Further cassette exchange transformations were carried out with the KmR 
donor plasmid pRM2 in order to allow checks of antibiotic resistance marker 
gain and loss as described in section 3.5.2.1. The reason for this change from 
the above pRM3 transformations and PCR check was because selection for 
pZJ7 uses a chloramphenicol CmR marker, which would interfere with 
selection for the CmR donor cassette from pRM3. On the other hand, pRM2 
features a KmR donor cassette (and ApR backbone), which does not clash with 
pZJ7. 
In repeated transformations of LPC311a / pZJ7 cells with the KmR donor 
plasmid pRM2, transformants showed sustained resistance to all three marker 
antibiotics (erythromycin, chloramphenicol and kanamycin) following several 
rounds of heat treatment. To check if any cassette exchange or integration 
was occurring in these transformants, several PCRs were designed to read 
across all four of the possible junctions expected for either cassette exchange 
or no cassette exchange, and were performed on a smaller number of 
colonies. A diagram explaining these PCRs is shown in Figure 3.16. 
According to expected band sizes indicated in the legend of Figure 3.16, 
successful cassette exchange should result in amplification from PCRs 3 and 4 
and no amplification from PCRs 1 and 2, and vice versa for no cassette 
exchange. These PCRs were performed on six kanamycin-resistant LPC311a / 
pZJ7 pRM3-transformed colonies (arabinose-induced protocol), labelled A to F, 
and products were run on an agarose gel, shown in Figure 3.17. 
Untransformed LPC311a was included as a cassette exchange negative control. 
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 Figure 3.17: Agarose gel of PCRs as shown in Figure 3.16, performed on 
LPC311a (negative control) and 6 arabinose-induced LPC311 / pZJ7 + pRM3 
transformants, labelled A+ to F+. The LPC311a negative control shows the 
expected bands for PCR1 and PCR2 of 1001 bp and 1331 bp, respectively, and 
no product for PCR3 and PCR4. Each of the six pRM3 transformants tested 
showed strong bands from PCRs 2 and 3, of sizes 1331 bp and 924 bp, 
respectively. This is different to what was expected from either successful or 
unsuccessful cassette exchange outcomes (as indicated in Figure 3.16). 
Complete integration of the KmR donor cassette should result in amplification 
in PCRs 3 and 4. From these results, it is clear that an alternative event to 
complete cassette exchange is occurring, resulting in the amplification of the 
upstream-KmR junction and the EmR-downstream junction of the landing pad. 
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Contrary to what was expected for the two expected possible outcomes, each 
pRM3 transformant amplified strongly for PCRs 2 and 3, with band sizes of 
1331 bp and 924 bp, respectively. This indicated that the erythromycin 
resistance marker gene is still present in its original position at the pepA locus 
upstream of attBTC and holC, while the kanamycin resistance marker has also 
been integrated at the start of the LP cassette.  
An explanation which is consistent with these results is that a whole plasmid 
integration has occurred. In this outcome, pRM3 integrates via recombination 
between attBTT on the genome and attPTT on the donor plasmid, but the 
second expected recombination reaction between attBTC and attPTC does not 
occur. A diagram of this outcome is shown in Figure 3.18.  
Whole integration of pRM3 into the attBTT LP site not only explains the PCR 
results observed, but also explains why cells were persistently resistant to 
kanamycin, ampicillin and erythromycin following several rounds of heat 
treatment, as the plasmid and all three resistance markers were integrated 
into the genome and could not be removed as a temperature-sensitive 
plasmid would be. 
Despite this undesired outcome being observed and complete cassette 
exchange being unsuccessful, the results shown in Figure 3.15 do reveal that 
recombination between attBTT and attPTT is highly efficient, and that 
integration of the whole plasmid at the pepA LP site has been observed at 
100% efficiency in all transformants tested. 
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3.5.3.  Sequencing the φC31 integrase LP on the LPC311a 
genome to investigate incomplete cassette exchange 
Due to the absence of recombination between attBTC on the genome LP and 
attPTC on the donor cassette, the sequences of both were checked. Using 
primers reading upstream and downstream of pepA (PCR2 from Figure 3.4) to 
amplify the whole landing pad region, a PCR was performed, and the product 
was purified and sent for sequencing (Eurofins Genomics). pRM3 was also sent 
for sequencing to check the sequence of the donor cassette.  
Sequences produced from the genomic LP PCR product were aligned with the 
desired sequence used to insert the LP into pepA by recombineering. This 
alignment is shown in Figure 3.19. From this alignment, it was revealed that a 
17 bp deletion was present in attBTC. This explains why recombination was not 
taking place between attBTC and attPTC, resulting in the integration of the 
whole pRM3 plasmid at attachment site attBTT.  
The next step of this study was to reestablish the φC31 LP in the pepA locus 
and ensure that the complete sequence was present without any deletions or 
mutations. This would then allow efficient cassette exchange to be 
demonstrated, following on from the high rates of plasmid integration that 
have been seen on the LPC311a LP with only one complete attB site. 
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3.6.  Discussion 
In this project, a protocol was established and tested which allowed the 
delivery of a φC31 integrase ‘donor cassette’ to a newly introduced site on 
the E. coli genome. This method made use of a temperature-sensitive delivery 
cassette which has not been used previously for serine integrase integration 
deliveries (Section 3.3; Methods Section 2.5). 
A key aspect of the protocol was the expression of φC31 integrase under 
control of the arabinose-inducible pBAD promoter. This overcame issues 
observed with constitutive expression of φC31 integrase in landing pad cells 
which resulted in low cell growth and conversion of the φC31 integrase 
expression plasmid to smaller plasmid products (Figures 3.9, 3.10 & 3.11). It is 
thought that this occurrence is connected to the presence of the attB sites on 
the genomic landing pad and a negative interaction with φC31 integrase, as 
this modification of the expression plasmid was not observed in non-LP 
containing E. coli DS941 cells. However, once expression was controlled via 
the pBAD inducible promoter, recombination efficiency was much higher as 
demonstrated using the GalK recombination assay in LPC311a cells (Figures 
3.12 & 3.13). 
Initially, it was found difficult to successfully establish the LP cassette in 
place in the E. coli pepA gene due to very low efficiencies seen from the 
recombineering method. This low efficiency integration rate is a good 
illustration of why an improved method for chromosomal integration of 
heterologous DNA is necessary. Once marker-positive transformant colonies 
were seen on selection plates, there were only around three to five colonies 
per plate. It was later seen that this recombineering integration also 
introduced a loss-of-function deletion in the attBTC attachment site of the LP 
(Figure 3.19), which also demonstrated the possible inaccuracies that can 
occur during recombineering. Unfortunately, this deletion within the LP 
attachment site was not noticed until late on in the project, meaning that a 
lot of time was spent trying to optimise a cassette exchange protocol despite 
the fact that the LP sequence was not as expected.  
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Taking into consideration the above limitation of the established LP only 
featuring one functioning attBTT attachment site, the results of donor plasmid 
transformations (under arabinose-induced φC31 integrase expression) can be 
viewed as whole plasmid integrations into a single chromosomally-integrated 
attBTT site. Under this assumption, it can be argued that integration reactions 
were in fact highly efficient. Of every marker-positive transformant, PCR 
amplifications of the LP site revealed that whole plasmid integration had 
occurred, indicating that this event is highly efficient and demonstrable. 
Given that this event occurred at such a high rate, it is likely that, if a full 
secondary attBTC (without deletion) were present, the second recombination 
reaction between attPTC and attBTC would occur (see Figure 3.18) equally 
efficiently to remove the remaining plasmid backbone and leave only the 
integration cassette remaining at the φC31 LP site.  
The next stage of this project was to demonstrate the described LP cassette 
exchange protocol with a pepA-located φC31 integrase LP that contains the 
two desired complete attBTT and attBTC sites without any deletions. At the end 
of this project, recombineering was being repeated in order to establish the 
correct LP sequence. Further plans were made to create an LP for Bxb1 
integrase in the same way. The design of this Bxb1 integrase LP was identical 
to that of the φC31 integrase LP but with the φC31 attBTT and attBTC sites 
replaced with 54 bp attBGT and attBGA sites for Bxb1 integrase, respectively, 
which are shown in Figure 3.20. 
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 Figure 3.20: Bxb1 integrase attB sites to be used in Bxb1 LP construction 
similar to the design shown in Figure 3.1 but with Bxb1 attachment sites 
attBGT and attBGA. 
Once LPs have been successfully demonstrated for cassette exchange further 
to the whole plasmid integrations shown here, these results can help to 
inform the design of a multi-integrase system in E. coli. Work done in the 
following chapters also aims to provide data on how LP cassette exchange 
efficiencies may differ between genomic locations (Chapter 4), whether there 
may be cross-reactivity problems when using multiple integrases (Chapter 5) 
and if this system can be successfully demonstrated in eukaryotic yeast cells 
(Chapter 6).  
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4.  Chapter 4: Random transposition of several 
φC31 LPs in E. coli 
4.1  Introduction 
So far in this project, a single gene locus, pepA, was targeted in order to 
establish and characterise LPs for φC31 integrase and Bxb1 integrase in the 
same context. However, previous studies have shown that chromosomal 
location can have a significant effect on integration efficiencies. For instance, 
it has been observed that genomic integrations using a single TG1 integrase 
site are more efficient when placed close to the E. coli genome origin of 
replication, oriC, or the E. coli ‘centromere’ analogue site migS, than other 
areas of the genome (Muroi et al., 2013). In order to determine the effect of 
chromosomal positioning on the efficiency of the φC31 integrase LP, a library 
of E. coli strains with the LP cassette inserted into different places on the 
genome was created. 
Expression levels in different genomic contexts are a factor in the design of 
reusable and tailored LP sites. An advantage of a multi-LP system is that 
expression levels are known and can be selected in order to fine-tune 
heterologous pathways. Engineering several LPs with different known natural 
levels of expression is also a convenient way to optimise heterologous gene or 
pathway expression without the need for switching promoter strength. 
Creating a large library of LPs with well characterised expression profiles 
would allow for an LP to be chosen based on its expression properties, an 
attractive prospect for integrating gene products that may need to be 
carefully regulated, for example in the case of toxic gene products whose 
levels need to be maintained below a certain threshold.  
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In order to determine the effect of chromosomal positioning on the 
characteristics of a φC31 integrase LP, a library of E. coli strains was created 
via random transposition of the LP cassette across the entire E. coli genome. A 
φC31 integrase LP library that was previously established in this lab (E. Conte, 
unpublished) was used as a basis for analysis in this project, which aimed to 
measure and compare cassette exchange efficiencies and heterologous gene 
expression levels between several random LP locations on the E. coli genome. 
4.2  Design of φC31 LP ISY100 transposition cassette 
and generation of E. coli LP library 
The φC31 integrase LP to be used in this experiment was designed to include 
both a selective antibiotic-resistance marker, KmR, and a counter-selective 
marker, rpsL, which confers sensitivity to streptomycin (Nair et al, 1993). 
These selective genes were flanked by attBTT and attBTC sites in a head-to-
head orientation identical to the initial φC31 integrase LP (EmR) previously 
designed in this project. The design of this LP is shown in Figure 4.1. 
 
Figure 4.1: Diagram showing design of the φC31 transposable LP featuring: a 
KmR marker for kanamycin resistance; rpsL counter-selectable marker for 
streptomycin sensitivity; flanking attBTT and attBTC landing pad sites for 
cassette exchange of an attPTT and attPTC-flanked target gene. 
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The transposase ISY100 was previously used in this lab to insert the KmR φC31 
LP into random positions in the E. coli DS941 genome (E. Conte, unpublished). 
The LP cassette was delivered via a plasmid (pZJ73; see Methods Section 2.5) 
into which it was cloned between two ISY100 terminal inverted repeat 
sequences. The ISY100 transposase expressed on the same plasmid facilitates 
integration of the transposable element, as defined by the ISY100 inverted 
repeat sequences, into TA dinucleotide sites on the genome, duplicating the 
TA upon transposition (Urasaki et al, 2002). The protocol for this plasmid 
transformation and library generation by random transposition can be found in 
Methods Section 2.18. 
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4.3  Determining the genomic locations of six randomly 
transposed φC31 LPs by arbitrary PCR 
From a library of around 1000 KmR φC31 LP-positive E. coli  (DS941) mutants, 
individual mutants were isolated by streaking out from library glycerol stocks 
onto LB agar plates containing kanamycin to obtain single colonies. Six 
mutants were selected for analysis and comparison of distant LP sites. In 
order to contextualise and characterise each of these landing pads within the 
E. coli genome, a two-step “arbitrary PCR” method was used to identify the 
location of each LP within the genome (see Methods  Section 2.19). This 
arbitrary PCR is designed to amplify from a specific sequence on the inserted 
cassette to arbitrary sequences on the genome. An explanatory diagram of 
this arbitrary PCR is shown in Figure 4.2.  
The first round of PCR used one primer that reads forward from a short 
sequence in the KmR gene of the LP cassette, and a second primer which 
consists of a sequence designed to anneal to a large number of possible 
sequences on the genome and a specific extension sequence (or tag). These 
primer sequences are shown in Methods Section 2.4 and the full method is 
described in Methods Section 2.19. This first arbitrary PCR produces a large 
number of products of varying sizes which have been amplified from different 
arbitrary locations on the genome to the LP KmR sequence. Using these 
products, a second PCR is performed using a forward primer which reads from 
just downstream of the first KmR primer, and a reverse primer which reads 
only from the extended (tag) sequence attached to the PCR products by the 
first arbitrary primer. The result is a cleaner and more concentrated PCR 
product that can be then sent for sequencing. 
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The amplified sequences from the arbitrary PCR were then sent for 
sequencing (Eurofins) and the results used to search the NCBI BLAST database 
for homology to a specific sequence on the E. coli substrain MG1655 (K-12), of 
which DS941 is a derivative. Results of the sequence alignments for the six 
KmR φC31 LP-positive E. coli  DS941 mutants tested are represented in Figure 
4.3. The relative positions of each randomly transposed φC31 LP on the E. coli 
genome is summarised in Figure 4.4, and the genomic context of each is 
detailed further in Table 4.1. 
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Figure 4.3a: BLAST sequence locations of three successful RTLP two-step 
arbitrary PCR product sequencing results, produced as alignments with the 
Escherichia coli str. K-12 substr. MG1655 reference genome in the NCBI 
genome explorer (https://www.ncbi.nlm.nih.gov/nuccore/NC_000913.3). The 
top bar of each window indicates location of the sequence alignment within 
the 4,641,652 bp reference genome, while below this the PCR-derived 
sequence (which begins immediately at the end of the transposed LP 
sequence) alignment is shown in context of its region on the genome including 
genes in this region (scale of sequences in this diagram are indicated at the 
bottom of each window). The three mutants are labelled as follows according 
to their sample reference and the gene in closest proximity on the genome: 
RTC31LP3 ftnB; RTC31LP5 umpG; RTC31LP7 ybiX. References are shortened to 
‘RTLP(n)’ elsewhere. 
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 Figure 4.3b: BLAST sequence locations of three successful RTLP two-step 
arbitrary PCR product sequencing results, produced as alignments with the 
Escherichia coli str. K-12 substr. MG1655 reference genome in the NCBI 
genome explorer (https://www.ncbi.nlm.nih.gov/nuccore/NC_000913.3). The 
top bar of each window indicates location of the sequence alignment within 
the 4,641,652 bp reference genome, while below this the PCR-derived 
sequence (which begins immediately at the end of the transposed LP 
sequence) alignment is shown in context of its region on the genome including 
genes in this region (scale of sequences in this diagram are indicated at the 
bottom of each window. The three mutants are labelled as follows according 
to their sample reference and the gene in closest proximity on the genome: 
RTC31LP8 ybdF; RTC31LP9 rutA; RTC31LP10 yhiM. References are shortened 
to ‘RTLP(n)’ elsewhere. 
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Table 4.1: List of confirmed RT φC31 LP mutants and their genomic 
locations, with reference to E. coli MG1655 (NCBI genome database). 
4.4  Confirmation of genomic LP locations by location-
specific PCR 
In order to double-check that the genomic LP positions determined by 
arbitrary PCRs and sequencing were correct, PCRs were designed with primers 
reading from the KmR marker on the φC31 LP to a 20 bp site on the genome 
under 1000 bp from the assumed LP location. The primers used are listed in 
Methods Section 2.4 and the PCR was done using an NEB Phusion Polymerase 
protocol (Methods Section 2.13.1) on a single colony of each RT LP mutant 
(diluted in distilled water before addition to reaction tube). DNA produced 
was cleaning using a QIAgen PCR Purification kit before being run in an 
agarose gel. This agarose gel is shown in Figure 4.5. 
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 Figure 4.5: Agarose gel showing the DNA produced in confirmation PCRs of 
randomly transposed φC31 LPs (KmR) for each of the six mutants tested. The 
expected product sizes for each LP mutant were as follows: RTLP3 (ftnB) 2313 
bp; RTLP5 (umpG) 1568 bp; RTLP7 (ybiX) 1860 bp; RTLP8 (ybdF) 1670 bp; 
RTLP9 (rutA) 1507 bp; RTLP10 (yhiM) 1700 bp. 
4.5  Designing and cloning a temperature-sensitive 
donor cassette plasmid compatible with KmR LP 
Cassette exchange experiments conducted with the randomly transposed KmR 
φC31 LPs required the cloning of a new temperature-sensitive donor cassette. 
In this case, the erythromycin resistance gene EmR, used as an LP marker in 
previous experiments, was cloned into the φC31 LP donor cassette of plasmid 
pRM1 (AmR backbone) between restriction sites NheI and NotI to create a new 
temperature-sensitive donor plasmid, pRM4 (detailed in Methods Section 2.5). 
Cassette exchange transformations can now be done as previously using the 
inducible φC31 integrase expression plasmid pZJ7 as described in Chapter 3.  
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4.6  Discussion 
Although cassette exchange experiments were not carried out during this 
work, the project has established and confirmed the genomic locations of six 
randomly inserted φC31 integrase LPs from the wider library previously 
created in this lab (E. Conte, manuscript in preparation). LP positions were 
first identified using a genome-wide arbitrary PCR and then confirmed using 
specific PCRs with primers that read forward from a sight upstream of the 
identified LP site and reverse from a sequence within the KmR gene. This 
contextual information can inform cassette exchange experiments to 
determine whether location on the genome has an effect on cassette 
exchange efficiency at the LP site.  
The six LPs identified represent a range of contexts. Three are integrated 
within the coding regions and three are in non-coding regions, and they are 
spread across the entire chromosome. This last consideration is important as 
it will be interesting to see whether LP cassette exchange efficiency will be 
increased nearer the chromosomal origin of replication, oriC, as this has been 
observed previously in studies that integrated plasmid DNA into single sites 
using TG1 integrase (Muroi et al., 2013). 
Cassette exchange experiments would use the same protocol developed in the 
previous chapter, expressing φC31 integrase under control of an arabinose-
induced promoter and transforming a temperature-sensitive donor vector, 
pRM4, described above which features an EmR marker flanked by attPTT and 
attPTC sites. Cassette exchange would then be detected by first selecting for 
erythromycin resistance, treating cells at 42°C to remove the donor plasmid, 
then checking to see the antibiotic resistances of the resulting cells in large 
numbers to determine what percentage of transformant colonies were 
successful for φC31 integrase-mediated cassette exchange. In these 
experiments, the rpsL counter-selectable marker can also be used to check if 
cassette exchange has taken place. If cells are sensitive to streptomycin, 
unsuccessful cassette exchange is indicated due to persisting presence of rpsL 
on the LP. However, if cells are streptomycin-resistant, this indicates that the 
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rpsL has successfully been replaced by the donor cassette on the LP. Finally, 
several transformants would be tested for cassette exchange using PCRs, as 
done in Chapter 3.  
After cassette exchange reactions with donor marker genes have been done to 
determine the comparative efficiency at each site, the effect of LP position 
on the expression levels of an integrated gene can be explored. The ability to 
choose from a number of genomic LP sites with different expression profiles 
would be of advantage to the proposed LP library system, as it would allow 
the user to select an LP to suit the desired expression levels of the target 
gene. Additionally, in a multi-integrase system, being able to choose LPs with 
higher or lower expression levels would be of interest in pathway optimisation 
when integrating several pathway genes.  
To test expression levels of each LP, a donor cassette consisting of a green 
fluorescent protein (GFP) gene flanked by attPTT and attPTC sites for φC31 
integrase would be introduced. If cassette levels of the LPs prove to be 
suitably high, there would be no need for a selective marker on this donor 
cassette. It will then be possible to dilute and plate GFP-transformed cells 
(without marker selection) to achieve single colonies. A high number of these 
colonies should then produce GFP, which will be detectable using a 
fluorescence imager. Using an imager which is able to quantifiably measure 
fluorescence levels will give an initial indication of expression level. However, 
measuring single colonies with a single copy of GFP on the chromosome will 
not accurately represent expression levels. A single GFP-positive colony could 
be used to inoculate an overnight starter culture of which the cell density 
would be measured, and then a known number of cells could be used to 
inoculate a fresh cell culture. This culture could then be used to measure 
fluorescence levels of a known number of cells in liquid culture, and levels 
could be compared between LP locations.  
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5.  Chapter 5: Investigating compatibility of 
integrases for a multi-LP system 
5.1  Introduction 
One of the most promising applications of the landing pad system is the use of 
several integrase LPs to allow multiplexed gene integrations into a single 
strain. Given the range of integrases now available for use, it may be possible 
to create a mutant with many serine integrase LPs (e.g. φC31.int, Bxb1.int, 
φBT1.int, TG1.int), into which several target genes can be integrated to 
introduce an entire metabolic pathway. Further possibilities are presented by 
the use of recombination directionality factors (RDFs), or integrase-RDF 
fusions, to perform additional rounds of cassette exchange. This chop-and-
change method could for example be used to analyse the effect of expressing 
an alternative or optimised gene within an already-integrated pathway, and 
would limit the steps required for strain optimisation. 
Serine integrases are by nature highly site-specific, yet there have been 
suggestions of cross-reactivity, of attachment site recognition and RDF 
interactions, between different integrases given the close relatedness of 
these enzymes (Singh et al, 2014). For example, φC31 integrase and TG1 
integrase share around 49% sequence identity (Rowley et al., 2008), which has 
led to suggestions that this level of shared sequence could result in cross-
interaction between these two integrases and their non-corresponding RDFs. 
For a multi-integrase LP system to be successful, cross-reactivity of the 
integrases and their RDFs must be investigated in order to address any cross-
compatibility issues. As well as providing results to inform the design of a 
multi-integrase LP system, the knowledge of to what extent serine integrases 
interact with each other’s attachment sites and RDFs is of use to the 
development of other systems, in particular for the serine integrase 
recombinational assembly (SIRA) (Colloms et al., 2013). 
Two of this group’s most-studied serine integrases, φC31 integrase and TG1 
integrase, are here investigated for the cross-compatibility of the integrase 
enzymes and their corresponding RDF proteins. TG1 integrase is a serine 
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integrase that has been shown to efficiently integrate heterologous DNA into 
pre-inserted att sites on the E. coli genome (Muroi et al., 2013), making it a 
prime candidate for use in the landing pad system. As previously mentioned, 
φC31 and TG1 integrase also share a high level of primary sequence identity, 
meaning that they are two enzymes from which some cross-interaction might 
be expected. The aim of this study was to determine to what extent φC31 
integrase and TG1 integrase and their RDFs, (gp3 and gp25 respectively), 
interact, and whether they could be used effectively within the same multi-
integrase system. Following this, the extent of attachment site orthogonality 
will be measured to determine whether it is possible for these serine 
integrases to recombine closely related att sites which feature high sequence 
identity. 
5.2  Measuring cross-compatibility of φC31 and TG1 
integrases and their corresponding RDFs 
5.2.1.  φC31 and TG1 integrase attL x attR recombination 
activation by non-native RDFs 
Serine integrases act to recombine attP and attB sites to integrate DNA and 
form product sites attL and attR in a highly unidirectional manner; this means 
that when only the integrase is present, no recombination occurs between 
attL and attR, and the reaction favours only integration. The reverse reaction 
(attL recombination with attR) proceeds only in the added presence of the 
integrase’s RDF. It is thought that RDF proteins bind to integrase subunits to 
end inhibition of the attL/attR reaction, and this integrase-RDF complex 
catalyses attL/attR recombination. This reverse recombination reaction 
usually requires the combination of an integrase and its own RDF. However, it 
has been suggested that some integrases may be activated by RDFs of other 
integrases, due to the closely related nature and presence of conserved 
sequences in these RDFs.  
Here, the integrases φC31 and TG1 and their respective RDFs gp3 and gp25 
are investigated for such cross-interactions in attL/attR recombination. This 
involves incubating each integrase and its native or non-native RDF with an 
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attL/attR substrate to determine to what extent opposite RDFs are able to 
facilitate this reaction compared to native RDFs. These reactions were first 
tested in vitro using a recombination assay similar to the one used in the 
integrase activity assay in Chapter 3 (see Section 3.4.1). Substrate plasmids in 
this case feature attL and attR sites and are designed for in vitro reactions; 
pFM52, featuring attL and attR sites for φC31 integrase and pFM139, featuring 
attL and attR sites for TG1 integrase. These plasmids are detailed in Methods 
Section 2.5. A diagram describing this in vitro recombination assay is shown in 
Figure 5.1.  
For each integrase, four reactions were set up: 1) no integrase, replaced by 
buffer IDB as negative blank; 2) integrase only; 3) integrase plus own RDF; 4) 
integrase plus non-native RDF. Recombination assay reactions were first set up 
by pre-incubating the integrase and RDF for 15 minutes at room temperature 
before adding the plasmid substrate (a full protocol is described in Methods 
Section 2.20). Initial reactions were run for either 30 minutes or 3 hours to 
determine whether incubation time had an effect on recombination 
efficiency. However, when results indicated that there was no discernible 
difference in result with a longer incubation, 30 minute incubation periods 
were used for all consequent reactions. Once reactions were completed, NruI 
was added to create linear products and DNA was run on an agarose gel.  
From photos of these agarose gels, relative DNA concentrations of the 
products of each reaction were quantified using ImageJ (see Methods Section 
2.23). This method gives the relative percentage of the DNA concentration of 
each band in each lane. Unrecombined DNA is seen as two bands at the top 
and bottom of each lane, while recombination results in two bands between 
these unrecombined bands (see Figures 5.1, 5.2 & 5.3 for more detail). 
Figures 5.2 and 5.3 show the agarose gels of the above in vitro recombination 
assays carried out with φC31 integrase and gp3 or gp25 (Figure 5.2), and TG1 
integrase with gp25 or gp3 (Figure 5.3), alongside graphs illustrating the 
recombination levels quantified from each gel lane according to Methods 
Section 2.23. 
 134
  135
Figure 5.1: In vitro assay for attL x attR recombination by φC31 integrase 
(pFM52, top) and TG1 integrase (pFM139, bottom). When incubated with 
purified integrase and RDF in vitro, attL x attR recombination results in 
two circular products featuring an attP or attB site, which are both 
linearised by the restriction enzyme NruI. In the case that no 
recombination between attL and attR occurs, the original substrate 
plasmid is cut to form two linear products of the sizes indicated.
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Figure 5.2: Agarose gel showing DNA from the in vitro attL x attR recombination 
assay of φC31 integrase with either native RDF gp3 or TG1 RDF gp25. The four lanes 
of the gel are as follows: 1) substrate pFM52 with IDB buffer as a negative control; 
2) pFM52 with φC31 integrase only; 3) pFM52 with φC31 integrase incubated with 
gp3; 4) pFM52 with φC31 integrase incubated with gp25. Figures below the gel 
image correspond to the percentage of substrate DNA in the gel that was 
recombined or unrecombined, calculated with ImageJ (see Methods 2.23). The 
percentage of substrate DNA recombined in each reaction is represented graphically 
below. These figures are estimates produced using computation analysis of the 
agarose gel image and do not represent precise DNA concentration measurements.
Recombined (%) 3.866 6.822 72.888 39.137
Unrecombined (%) 96.133 93.178 27.112 60.863
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Recombined (%) 4.555 9.306 72.359 11.237
Unrecombined (%) 95.445 90.694 27.641 88.763
Figure 5.3: Agarose gel showing DNA from the in vitro attL x attR recombination 
assay of TG1 integrase with either native RDF gp25 or φC31 RDF gp3. The four lanes 
of the gel are as follows: 1) substrate pFM139 with IDB buffer as a negative control; 
2) pFM139 with TG1 integrase only; 3) pFM139 with TG1 integrase incubated with 
gp25; 4) pFM139 with TG1 integrase incubated with gp3. Figures below the gel 
image correspond to the percentage of substrate DNA in the gel that was 
recombined or unrecombined, calculated with ImageJ (see Methods 2.23). The 
percentage of substrate DNA recombined in each reaction is represented graphically 
below. These figures are estimates produced using computation analysis of the 
agarose gel image and do not represent precise DNA concentration measurements.
It would naturally be expected that only an integrase’s native RDF would be 
able to activate attL x attR recombination. However, results observed here 
show that TG1 gp25 is able to significantly activate φC31 integrase attL x attR 
recombination. The agarose gels of Figure 5.2 show that incubating φC31 
integrase with gp25 (Figure 5.2, lane 4) produces a large amount of 
recombination product, with 39% of the substrate DNA recombined according 
to digital quantification of the DNA bands. However, it should be noted that 
this recombination is less efficient than the natural gp3 activation of φC31 
(Figure 5.2, lane 3), which recombined 73% of the substrate DNA.  
Interestingly, the reverse does not appear to be true, as φC31 gp3 did not 
activate TG1 integrase attL x attR recombination at the same level (Figure 
5.3, lane 4), with only 11% of the substrate plasmid recombined. This number 
is very close to the recombination level seen in the reaction containing only 
TG1 integrase without an RDF (9% recombination; Figure 5.3 lane 2). This 
demonstrates the low level of attL x attR recombination that TG1 integrase is 
capable of even in the absence of an RDF.  
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5.2.2.  Inhibition of φC31 and TG1 integrase attP x attB 
recombination by φC31 gp3 and TG1 gp25 RDFs 
In addition to activating attL x attR recombination, RDFs have been shown to 
have an inhibitory effect on the reverse attP x attB reaction (Khaleel et al., 
2011). After finding that TG1 gp25 is able to activate φC31 integrase attL x 
attR recombination, the next step was to determine to what extent these 
RDFs exerted an inhibitory effect on attP x attB recombination for each 
integrase. This was again done using an in vitro recombination assay almost 
identical to that above but instead using substrate plasmids featuring attP and 
attB sites. The plasmids in this case were pFM16 (φC31 attP/attB) and pFM138 
(TG1 attP/attB), which are detailed further in Methods Section 2.5. A diagram 
detailing this in vitro recombination assay and product sizes is shown in Figure 
5.4.  
The in vitro recombination assay was carried out as before, with a 15 minute 
pre-incubation of the integrase and RDF at room temperature before adding 
the substrate plasmid and incubating for 30 minutes (detailed further in 
Methods Section 2.20). After the reaction was stopped, NruI was added and 
the resulting linear products were run on an agarose gel, which are shown in 
Figures 5.5 (φC31 and substrate pFM16) and 5.6 (TG1 and substrate pFM138), 
alongside graphs illustrating the recombination levels quantified from each gel 
lane according to Methods Section 2.23. 
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Figure 5.4: In vitro assay for attP x attB recombination by φC31 integrase (pFM16, 
top) and TG1 integrase (pFM138, bottom). When incubated with purified integrase in 
vitro, attP x attB recombination results in two circular products featuring an attL or 
attR site, which are both linearised by the restriction enzyme NruI. In the case that no 
recombination between attP and attB occurs, the original substrate plasmid is cut to 
form two linear products of the sizes indicated.
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Figure 5.5: Agarose gel showing DNA from the in vitro attP x attB recombination 
assay of φC31 integrase with either native RDF gp3 or TG1 RDF gp25. Two gels are 
shown, A and B, with lanes as follows: A1) substrate pFM16 with IDB buffer as a 
negative control; A2) pFM16 with φC31 integrase only; A3) pFM16 with φC31 
integrase incubated with gp3; B1) substrate pFM16 with IDB buffer as a negative 
control; B2) pFM16 with φC31 integrase only; B3) pFM16 with φC31 integrase 
incubated with gp25. Figures below the gel image correspond to the percentage of 
substrate DNA in the gel that was recombined or unrecombined, calculated with 
ImageJ (see Methods 2.23). The percentage of substrate DNA recombined in each 
reaction is represented graphically below. These figures are estimates produced 
using computation analysis of the agarose gel image and do not represent precise 
DNA concentration measurements.
Recombined (%) 1.464 49.271 10.663 2.354 66.639 52.043
Unrecombined (%) 98.536 50.729 89.337 97.646 33.361 47.957
A1	                A2	           A3 B1	                B2	           B3
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Recombined (%) 2.687 77.514 7.685 2.933 77.006 22.162
Unrecombined (%) 97.313 22.486 92.315 97.066 22.994 77.838
A1	                A2	           A3 B1	                B2	           B3
Figure 5.6: Agarose gel showing DNA from the in vitro attP x attB recombination 
assay of TG1 integrase with either native RDF gp25 or φC31 RDF gp3. Two gels are 
shown, A and B, with lanes as follows: A1) substrate pFM138 with IDB buffer as a 
negative control; A2) pFM138 with TG1 integrase only; A3) pFM138 with TG1 
integrase incubated with gp25; B1) substrate pFM138 with IDB buffer as a negative 
control; B2) pFM138 with TG1 integrase only; B3) pFM138 with TG1 integrase 
incubated with gp3. Figures below the gel image correspond to the percentage of 
substrate DNA in the gel that was recombined or unrecombined, calculated with 
ImageJ (see Methods 2.23). The percentage of substrate DNA recombined in each 
reaction is represented graphically below. These figures are estimates produced 
using computation analysis of the agarose gel image and do not represent precise 
DNA concentration measurements.
The attP x attB recombination assay results shown in Figures 5.5 and 5.6 
firstly demonstrate how each integrase’s own RDF inhibits attP x attB 
recombination. This activity is particularly evident in TG1 integrase. When its 
RDF gp25 is added, recombination of the attP and attB substrate was shown to 
decrease from 76% to 7% (Figure 5.6, gel A), indicating a significantly strong 
inhibition of the reaction. While for φC31 integrase this inhibition was not a 
strong, adding gp3 to the reaction still had an inhibitory effect, decreasing 
recombination from 49% to 11% (Figure 5.5, gel A). 
Interestingly, while TG1 RDF gp25 was shown in Figure 5.2 to activate φC31 
integrase attL-attR recombination (and the reverse was not true, with φC31 
gp3 shown not to activate TG1 integrase attL-attR recombination; Figure 5.3), 
in the case of attP-attB inhibition, gp25 appeared not to inhibit the forward 
reaction significantly (Figure 5.5, lane B3). Unexpectedly, it was φC31 gp3 
that had a more significant effect on TG1 attP-attB recombination inhibition, 
with its addition reducing the level of substrate DNA recombined from 77% to 
22% (Figure 5.6, lanes B2 & B3). 
5.3  Discussion 
The results presented here illustrate the high unidirectionality of φC31 and 
TG1 integrase when recombining attP and attB sites. Without the presence of 
gp3 or gp25, integrase enzymes show no or very little recombination of 
integrase product sites attL and attR (Figures 5.2 & 5.3). The naturally high 
level of recombination between attP and attB for both φC31 and TG1 
integrase can be seen in Figures 5.5 and 5.6, for which integrase and 
substrate were only incubated for a total of 30 minutes before stopping the 
reaction. Additionally, the low activity of each integrase on attL x attR sites 
without RDF demonstrates how the integration reaction occurs in a strongly 
unidirectional manner. This characteristic of the serine integrases is important 
for their application in the landing pad system as it ensures that high 
efficiency of integration can be achieved without any reverse flow of the 
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reaction. High efficiency of cassette exchange will allow the landing pad-
mediated genomic integration method to forgo the rate-limiting selection and 
screening process during strain development.  
Concerning the reverse reaction between attL and attR, both integrases were 
shown to display a high level of recombination when pre-mixed with their own 
RDFs (Figures 5.2 & 5.3), as expected. However, when φC31 integrase was 
mixed with the TG1 RDF gp25, it also displayed a significant level of attL x 
attR recombination (Figure 5.2). Previous amino acid sequence alignments 
between φC31 and TG1 integrase have revealed that they share a sequence 
identity of 63.8% in the catalytic N-terminal of the enzyme (49.5% identity 
overall) (Morita et al., 2009). It is apparent that interaction is occurring 
between φC31 integrase and TG1 gp25, however this interaction is not 
similarly seen between TG1 integrase and φC31 gp3, suggesting that each of 
these RDFs interact slightly differently with the integrase enzyme. However, 
further binding experiments will be required to determine the nature of these 
protein interactions. Current evidence suggests that the RDF interacts with 
the coiled-coil domain of the integrase C-terminal, a region which is thought 
to facilitate formation of the synaptic complex and control directionality of 
attB/attP and attL/attR recombination (Rutherford & Van Duyne, 2014).  
Inhibition of attP x attB recombination by addition of RDF was seen with both 
integrases and their native RDFs. This effect was particularly strong in the 
case of TG1 integrase, with addition of gp25 completely preventing attP x 
attB recombination (Figure 5.6, lane A3). This result supports the potential of 
TG1 integrase and gp25 being used for secondary cassette switching in a multi 
integrase/RDF LP system, in which a second target gene could be switched in 
(following expression of the integrase and its RDF) using the attL/attR sites 
produced by initial cassette exchange. The product sites of this secondary 
cassette exchange could then be used to switch in another attP donor 
cassette, and so on. However, it will be important to consider the observation 
that gp25 is capable of facilitating φC31 integrase attL x attR recombination 
in any multi-integrase system, as there could be complications of using φC31 
and TG1 integrase for attL x attR reactions in the same cells. 
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An interesting and unexpected result is the inhibition of TG1 integrase attP-
attB recombination by φC31 RDF gp3. It would be reasonable to expect that, 
due to gp25’s activating activity of attL-attR recombination by φC31 integrase 
(and the lack of activiation of TG1 attL-attR recombination by gp3), it would 
be gp25 that would have the higher inhibitory effect on φC31 integrase. 
However, what was observed is that φC31 gp3 has a much higher inhibitory 
effect on TG1 integrase attP-attB integrase. However, it is worth noting that 
the relationship between RDF concentration on attL-attR activation and attP-
attB inhibition was not explored extensively in this work. Further dosage 
effect experiments, in which a very low concentration of RDF is added and 
increased in small increments over time, may be necessary to determine the 
true inhibitory effect of each RDF on other integrases. 
While these experiments show that φC31 integrase interacts with TG1 gp25 in 
vitro, further experiments need to be done to determine to what extent this 
occurs within the cell. It will be important to determine whether φC31 gp3 
interacts with TG1 integrase in vivo despite this cross-reactivity not being 
apparent in vitro. The basis for this thinking is that this interaction may be 
more likely to take place in vivo as a larger concentration of RDF would be 
accrued when expressing the protein from a plasmid in the cell. This 
increased concentration of RDF might be capable of tipping the equilibrium to 
favour attL x attR recombination. If this were the case, control of both 
integrase and RDF expression by inducible promoters might be necessary.  
Another candidate serine integrase for use in an LP system is φBT1. However, 
there is also strong evidence that φBT1 gp3 and φC31 gp3 are interchangeable 
in vitro and in vivo (Zhang et al., 2013), with both RDFs sharing an 85% 
sequence identity. Given the results from this study, it will be interesting to 
observe whether a similar cross-interaction occurs between φBT1 integrase, 
TG1 integrase and their RDFs. It has also been suggested that φBT1 integrase 
is capable of recombining attL and attR sites at a low level in the absence of 
φBT1 gp3. This will need to be investigated if designing a φBT1 LP, as it would 
reduce the high efficiency required for markerless cassette exchange. 
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A significant basis of the multiple landing pad system and other multi-
integrase systems, such as serine integrase recombinational assembly (SIRA), 
is the specificity of an integrase for its own attachment sites. Due to 
similarities in their att site sequences, it will be important to establish the 
fidelity of each integrase to its own att sites and not those of other 
integrases. To this end, recombination experiments should be done both in 
vivo and in vitro, combining each integrase with attP/attB substrates from 
other integrases. Thus it will be seen to what extent an integrase is able to 
recombine att sites of another enzyme, and whether these integrases could 
be successfully used within the same multiplexed system. 
Further experiments to characterise serine integrases for use in a multi-LP 
system should also focus on the orthogonality of crossover sites within att 
sites. The LP system relies on the paradigm that att sites recombine only with 
other att sites containing identical central dinucleotide crossovers. 
Mechanistically, non-complementary central pairings should not be able to 
ligate with one another, preventing the final ligation step of recombination. 
However, in vivo, due to the existence of DNA repair mechanisms, it may be 
possible for cells to ‘fix’ the mismatching problem and proceed with 
recombination. Therefore, for each integrase, in vitro and in vivo 
recombination assays should be carried out (Methods Sections 2.20 & 2.21) 
using plasmid substrates containing an attP and attB site with non-matching 
central dinucleotides. 
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6. Chapter 6: Demonstrating a landing pad in 
Saccharomyces cerevisiae 
6.1.  Introduction 
While demonstrating and establishing that the serine integrase landing pad 
system in Escherichia coli has useful applications in strain development and 
optimisation for biotechnology, demonstrating the same system in eukaryotic 
cells is of equal or perhaps greater significance. Several industrially important 
microorganisms are eukaryotic and therefore present a more complex cellular 
context for genomic cassette integrations. The yeast Saccharomyces 
cerevisiae is a keystone of the biotechnology industry and has long been used 
as a host for producing commercial enzymes, biopharmaceuticals and 
biofuels, due to its well-understood characteristics and long history of use in 
the fermentation industry. This makes S. cerevisiae a key candidate for the 
further expansion and development of the landing pad system, as well as 
leading the way for the export of the LP to other eukaryotic industrially-
relevant microorganisms such as Pichia pastoris.  
In addition, demonstrating the use of serine integrases in eukaryotic cells 
could provide a basis for further research into the use of these enzymes in 
more complex multicellular eukaryotes for applications such as creation of 
transgenic lab animals or for gene therapy. φC31 integrase has already been 
demonstrated to function successfully in several experimentally relevant 
organisms, with studies conducted in Drosophila (Groth et al., 2004, Bischof 
et al., 2007, Bateman et al., 2006); however most of these studies relied on 
the existence of att-like psuedosites on the genome. φC31 integrase has also 
similarly been used in mammalian cells such as mice and human embryonic 
stem cells (Thyagarajan, et al., 2001), either using pseudo-sites or single 
inserted attP sites for integration of whole plasmids. 
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Employing the landing pad system in S. cerevisiae will both establish a highly 
useful tool for strain development and begin the development of a potential 
multi-LP yeast strain similar to that described for E. coli earlier in this thesis. 
Characterising the LP platform in this eukaryotic microorganism will also 
determine whether the same system could feasibly be used in yet more 
complex multicellular eukaryotes such as Drosophila, mice, or mammals used 
in experimental biology. In this chapter, a φC31 integrase LP tailored for use 
in S. cerevisiae was designed and targeted to several locations on the yeast 
genome. These LPs will be spread across a single yeast chromosome in order 
to determine the effect of location, for example proximity to the centromere 
or telomeres, on integration efficiency. 
6.2.  Establishing a φC31 LP at several loci on the S. 
cerevisiae genome 
6.2.1.  Designing a S. cerevisiae φC31 LP 
The φC31 integrase landing pad to be used in S. cerevisiae consists of the 
same attBTT and attBTC sites in a head-to-head orientation as the E. coli LP; 
however, the marker chosen is changed for use in yeast. In this case, the 
marker gene is a yeast auxotrophic selection marker, URA3. The URA3 marker 
gene can be used in yeast strains which are auxotrphic for uracil production 
and ordinarily require addition of uracil to the growth medium in order to 
grow. When URA3 is introduced into a uracil-negative strain, its ability to 
produce uracil is restored and it is able to grow on media lacking uracil. The 
URA3 marker is also chosen here for its counter-selectable property. Loss of 
URA3 can be detected by growth on media containing 5-fluoroorotic acid (5-
FOA). This is possible because the gene product of URA3, orotidine 5’-
phosphate decarboxylase, converts 5-FOA to a toxic product, 5-fluorouracil, 
resulting in cell death. Therefore URA3 was chosen as a versatile marker 
which can be used for detection of the LP when established, and later for 
counter-selection during LP-donor cassette exchange experiments. A diagram 
of the φC31 integrase S. cerevisiae LP is shown in Figure 6.1. 
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Figure 6.1: Diagram representing the design of a φC31 integrase LP for use in 
S. cerevisiae, featuring the URA3 auxotrophic selection marker flanked by 
φC31 attBTT and attBTC sites in a head-to-head orientation. 
6.2.2.  Selecting genomic locations for LP integration 
This project makes use of a library of yeast knockout strains established by 
the Saccharomyces cerevisiae Genome Deletion Project (Cherry et al, 2012). 
The Genome Deletion Project was set up to facilitate phenotypic analysis of 
every open reading frame in the yeast genome, and yielded a library of 
knockout strains in which each open reading frame has been replaced by the 
KanMX (kanamycin-resistant) deletion cassette. This is of use to this LP 
project as it presents the opportunity to be able to insert the LP cassette into 
any gene in the yeast genome via homologous recombination using the same 
KanMX-targeting homology sequences. From the Genome Deletion Project 
library, five mutant strains were selected with the KanMX knockout located at 
sites spread evenly across Chromosome IV. A table describing these genes and 
their locations is shown in Table 6.1 and their estimated relative positions 
represented in Figure 6.2.  
These gene locations were chosen on the basis that their knockouts are viable 
and have no or little competitive disadvantage. One gene was selected in the 
centromeric region (G9/YDR007W) in order to investigate whether proximity 
to the centromere affects integration efficiency. Four of these knockouts (G9/
YDR007W, D2/YDR138W, E11/YDR297W, G5/YDR539W) are located in a region 
of Chromosome IV with a high concentration of transposable elements; it is 
thought that this might effect the efficiency of LP integrations due to this 
region being naturally more physically open and available to transposases, for 
example having longer stretches of nucleosome-free chromosomal DNA. 
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Table 6.1: KanMX gene knockouts chosen to be targeted for insertion of 
the φC31 integrase LP cassette with details of mutant phenotypes 
(Cherry et al, 2012). 
 
Figure 6.2: A diagram representing the approximate relative positions of each 
of the 5 genes selected on S. cerevisiae Chromosome IV. 
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6.2.3.  Inserting the φC31 LP into KanMX marker library strains 
by homologous recombination 
6.2.3.1  Cloning of φC31 LP KanMX knockout delivery plasmid 
The method chosen for inserting the φC31 integrase LP into the KanMX yeast 
mutants was homologous recombination. This makes use of the endogenous 
DNA repair mechanism and requires the introduction of the desired LP 
cassette with flanking homology sequences to the target KanMX gene. When 
transformed into the cell, homologous sequences are recombined, with the 
KanMX cassette being replaced by the LP cassette. This mechanism is 
represented in Figure 6.3. 
The URA3 φC31 LP with flanking KanMX homology was introduced into yeast 
cells for homologous recombination via a delivery plasmid. The E. coli cloning 
vector pMTL23 was selected as a delivery plasmid, which features a CoIE1 
origin and ampicillin resistance gene. As this plasmid was only being used for 
delivery of the cassette and didn’t need to be propagated in S. cerevisiae, it 
was sufficient for all cloning steps to be done in E. coli. This also overcame 
the problem of removing the delivery plasmid after transformation. The 
regions of homology to be used for homologous recombination were chosen as 
120 bp at the very start (positions 1-120) and 120 bp at the very end (positions 
1238-1358) of KanMX. These sequences were synthesised as a single gBlock 
oligonucleotide (from Integrated DNA Technologies), featuring restriction sites 
for cloning flanking and separating the two homology sequences, shown in 
Figure 6.4. 
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            AscI      BamHI                              KanMX Start 1..120 
5’  GGCGCGCCGGATCCGACATGGAGGCCCAGAATACCCTCCTTGACAGTCTT 
GACGTGCGCAGCTCAGGGGCATGATGTGACTGTCGCCCGTACATTTAGCCCAT 
            NheI      BclI      FseI      ScaI 
ACATCCCCATGTATAATCATTTGCATCCATAGCTAGCTGATCAGGCCGGCCAGTA 
        EagI     BglII                                 KanMX End 1238..1358 
CTCGGCCGAGATCTTCAAATGTTAGCGTGATTTATATTTTTTTTCGCCTCGACAT 
CATCTGCCCAGATGCGAAGTTAAGTGCGCAGAAAGTAATATCATGCGTCAATCG 
                                                    XhoI     SpeI 
TATGTGAATGCTGGTCGCTATACTGCTCGAGACTAGT  3’ 
Figure 6.4: Sequence of KanMX homology gBlock with featured restriction 
sites for cloning into delivery vector pMTL23 and consequent cloning of LP 
cassette. The restriction sites used for cloning of the delivery vector are 
highlighted in bold (BamHI, NheI, BglII and XhoI), with the other restriction 
sites included for possible downstream cloning applications. 
 153
The KanMX homology gBlock was cloned into pMTL23, replacing the existing 
polylinker, using restriction enzymes BamHI and XhoI. Restriction mapping was 
used to confirm the insertion of the gBlock fragment, followed by sequencing 
using forward primer M13-for upstream of the replaced polylinker and reverse 
primer M13-rev reading 3’ to 5’ from the end of the cloned site. This 
intermediate plasmid is referred to as pMTL23-KanMX for the following steps. 
  
The URA3 φC31 integrase LP was taken from a previously cloned LP cassette 
(see Methods Section 2.5), which features the φC31 LP sequence as shown in 
Figure 6.1, flanked by restriction sites NheI upstream of attBTT and BglII 
downstream of attBTC. In order to use these restriction sites for correct 
cloning of the LP cassette into pMTL23, it was necessary to remove an 
additional NheI restriction site that was present in the pMTL23 backbone. This 
was done by partial digest using the restriction enzyme BmtI, an NheI 
isoschizomer which cuts to leave a 3’ overhang, allowing for end filling with 
Pfu polymerase and blunt-ended re-ligation to remove the NheI site. The 
removal of the NheI site was confirmed by restriction mapping and 
consequent sequencing. 
The yeast URA3 φC31 LP delivery plasmid, designated pRM5, was 
consequently constructed by digesting the landing pad cassette from pYLP1 
and pMTL23-KanMX vector construct using restriction enzymes NheI and BglII. 
The digested LP insert and pMTL23-KanMX vector were then purified by 
agarose gel electrophoresis and ligated to produce pRM5, shown in Methods 
Section 2.5. 
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6.2.3.2  Replacing KanMX with a URA3 φC31 LP by homologous 
recombination 
φC31 LP KanMX replacement plasmid pRM5 was introduced into each of the 
five chosen KanMX yeast knockout strains via a lithium acetate yeast 
transformation method described in Methods Section 2.22. Transformed cells 
were plated onto SD-uracil (SD media minus uracil) plates to select for URA3. 
To test for replacement of the KanMX gene with the URA3 φC31 LP cassette 
via homologous recombination, transformants were subsequently patched 
onto two selective plates. Firstly, to further test for presence or absence of 
URA3, cells were patched onto SD-uracil agar where growth would only be 
possible under expression of URA3, therefore confirming presence of the URA3 
LP. To test whether the KanMX cassette had been knocked out from the 
genome and replaced by the φC31 LP, transformants were secondly patched 
onto nutrient-complete YPD agar plus G418 (a kanamycin analogue). If cells 
are G418-resistant and grow on this media, the presence of KanMX is 
indicated. 
Following transformation with pRM5, each KanMX mutant tested positive for a 
URA3+ phenotype when selected on SD-uracil plates, and did not grow on 
YPD+G418, phenotypically confirming the replacement of KanMX with the 
φC31 LP (URA3). These plates are shown in Figure 6.6, including as controls 
the non-KanmX mutant origin S. cerevisiae strain (WT) and the untransformed 
KanMX mutants. 
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 Figure 6.6: Photographs of yeast KanMX mutants transformed with φC31LP 
homologous recombination plasmid pRM5 (alongside untransformed controls 
and ‘WT’ yeast) patched onto confirmation agar plates. Growth on SD-uracil 
plates indicates presence of the URA3 marker gene, while growth on YPD + 5-
FOA indicates continued presence of the KanMX cassette. 
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Following the phenotyping of URA3 LP transformants on selective plates, a 
further confirmation was done by PCR. Primers were designed to read from 
outside of the KanMX regions up- and down-stream of the LP into the URA3 
gene, as shown in Figure 6.7a. PCRs were performed on a single uracil-
positive transformant colony as described in Methods 2.13.1. Both PCRa, 
reading from an upstream KanMX sequence to URA3, and PCRb, reading from 
URA3 to a downstream KanMX sequence, amplified the expected product size 
in the LP transformants only, with no amplification in the WT background 
strain or untransformed KanMX starter strains. Gel electrophoreses of these 
PCRs are shown in Figure 6.7. 
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While these PCRs appear to confirm presence of the URA3 LP on the genome 
of these yeast transformants, it should be noted that due to the KanMX 
primers reading from within the regions of homology used for homologous 
recombination, there is a small but unlikely chance that the entire cassette 
could have inserted into a different location on the genome. Further 
confirmatory PCRs with primers reading from upstream and downstream of 
the deleted gene region are to be designed. Despite the above caveat, this 
appears to be a strong indication that the KanMX cassette has been 
successfully replaced by the φC31 LP. Colonies of each confirmed LP mutant 
were therefore grown in an overnight culture and glycerol stocks were made 
and stored at -80°C, labelled according to their LP gene deletion reference: 
F8/YDL229W, D2/YDR138W, G9/YDR007W, E11/YDR297W and G5/YDR539W. 
6.3.  Discussion 
Demonstrating the φC31 integrase LP described in this project in yeast would 
show its versatility and potential to be used in different industrially-relevant 
microorganisms, including eukaryotic cells. Much research has been done into 
the use of serine integrases for genome editing in eukaryotes, however the 
novelty of this method stems from the fact that the LP system uses two non-
identical attachment sites for a single integrase enzyme, rather than two 
different recombinases as in the RMCE and DICE methods (Turan et al., 2011; 
Geisinger & Calos, 2014), making this method of genome-based cassette 
exchange simpler than other systems. With a more complex chromosomal 
structure and cellular environment, it is likely that position of the integrase 
LP on the chromosome will have a greater impact on the efficiency of 
cassette exchange, making it more important to determine locations of high 
cassette efficiency in the development of a yeast-based LP system. In this 
work, five φC31 LP mutants were established, with LP locations spread across 
the length of S. cerevisiae S288C chromosome IV (Table 6.1 & Figure 6.2). 
These φC31LPs, featuring the selectable and counter-selectable URA3 marker 
gene, were established via homologous recombination, and confirmed both by 
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initial phenotypic analysis (for uracil prototrophy and loss of kanamycin 
resistance; see Figure 6.6) and by PCR confirmation (Figure 6.7). 
Once the five φC31 LP mutants were created, some problems were 
encountered during a wider phenotype of the mutant strains. When cells 
taken from glycerol stocks of the φC31 LP mutants were tested for 
auxotrophies, phenotypes were not as expected, bringing into question firstly 
the correct phenotype background of the KanMX strains used here and 
secondly whether there could have been contamination during creation of the 
glycerol stocks. At the end of this project, mutants were being further tested 
to confirm whether they were haploid, as expected, or diploid, which would 
explain the phenotypes seen during analysis. Depending on these tests, 
establishment of the correct haploid LP mutants via sporulation would allow 
subsequent LP cassette exchange experiments to be conducted with a 
plasmid-borne donor cassette consisting of an antibiotic marker gene flanked 
by φC31 attPTT and attPTC sites. The efficiency of these cassette exchange 
reactions could then be compared between each of the five LP sites on 
chromosome IV to determine whether genomic location has a significant 
effect, if any, on integration efficiencies in yeast. 
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7.  Chapter 7: Discussion 
7.1.  Establishing a φC31 integrase landing pad system 
in E. coli 
The overarching aim of this project was to demonstrate a serine integrase 
landing pad method in E. coli, with a view to eventually creating a multi-
integrase landing pad system to allow for genomic integration of multiple 
heterologous genes or whole pathways. Previous work had shown that serine 
integrases are able to efficiently integrate large lengths of DNA into single 
sites on the E. coli genome with high efficiency (Muroi et al., 2013). The 
previously developed recombinase-mediated cassette exchange (RMCE) 
method, in which tyrosine recombinases were used for cassette exchange at a 
site consisting of two non-identical attachment sites flanking a marker gene 
(Turan et al., 2011), also formed a basis for developing the serine integrase 
landing pad system.  
In this work, a landing pad cassette was designed for φC31 integrase, 
consisting of two attB sites in a head-to-head orientation (with differing 
central dinucleotides of TT and TC) surrounding a marker gene for 
erythromycin resistance. This cassette was inserted into the E. coli genome to 
replace the non-essential pepA gene via recombineering. While initial 
confirmation tests of the recombineering insertion indicated that the LP 
cassette had been successfully inserted into the pepA gene, a 17 bp deletion 
in the LP’s attBTC site went undetected during consequent cassette exchange 
experiments. The lack of cassette exchange detected in the initially-created 
LPC311a was at first attributed to inactivity of the φC31 integrase enzyme.  
Recombination activity assays performed in LPC311a revealed that the φC31 
integrase expression plasmid was being broken up and selected against by the 
cells, suggesting that it was having a toxic effect on cells containing the 
landing pad. This effect was successfully navigated by switching to an 
arabinose-inducible φC31 integrase expression plasmid, avoiding the build up 
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of the enzyme in the cells before it was needed. The system developed here 
now allows for φC31 integrase expression to be switched on immediately prior 
to transformation, and resulted in strong activity in in vivo recombination 
assays. 
Due to the 17 bp deletion that was found in the φC31 integrase LP attBTC site, 
cassette exchange experiments were performed in E. coli cells that contained 
only on viable attBTT site. This meant that the result of donor plasmid 
transformation, under expression of φC31 integrase, resulted in integration of 
the complete 4306 bp donor plasmid (pRM3) by attBTT x attPTT recombination. 
This considered, the results observed from cassette exchange reactions can be 
viewed as a demonstration of the efficient integration of 4 kb DNA at the 
target site. From these experiments, each set of 100 transformant colonies 
were positive for the three antibiotic resistance markers of the plasmid 
backbone, donor cassette and LP cassette, indicating that whole plasmid 
integration at the pepA φC31 LP attBTT site occurred in all colonies tested. 
This result is supported by previous genomic integration studies using TG1 
integrase which demonstrated integration of entire plasmids into introduced 
single attP or attB sites on the E. coli genome at high efficiencies (Hirano et 
al., 2011; Muroi et al., 2013). 
It is worth noting that in the time since the start of this project, progress has 
been made on other cassette exchange methods similar to that of the landing 
pad system described here. The recombinase-mediated cassette exchange 
(RMCE) method has been advanced to create a dual RMCE system in which the 
two attachment sites in the system are for two different tyrosine 
recombinases, Cre and Flp, rather than variations on the attachment sites of 
the same recombinase enzyme (Voziyanova et al, 2017). However, the ability 
of tyrosine recombinases to also catalyse the reverse excision reaction still 
means that this system is not as efficient as is possible with the more 
unidirectional serine integrases. 
A serine integrase-based genomic cassette exchange method resembling the 
landing pad system described here has also been developed for gene 
integrations in mammalian cells. Referred to as dual integrase cassette 
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exchange (DICE) (Geisinger & Calos, 2014), this system differs in that it uses 
two integrases for a single landing pad, making use of both a φC31 and a Bxb1 
att site as part of the same landing pad-like cassette. In this method, a 
cassette consisting of a φC31 attP site and a Bxb1 attP site flanking a kan/
neoR gene and GFP is pre-inserted into the genome of human embryonic stem 
cells. A donor plasmid featuring the corresponding φC31 attB and Bxb1 attB 
sites flanking the target gene and an mCherry marker gene is then co-
transfected into the cell with expression plasmids for φC31 integrase and 
Bxb1 integrase, resulting in cassette exchange across the site (Zhu et al, 
2014; Farruggio et al, 2017). This method has shown high specificity and 
efficiency, however in comparison to the single integrase LP system described 
in this study, DICE is complicated by the need to transform or transfect two 
integrase expression vectors alongside the donor plasmid. 
Since the start of this project the list of integrases available for use in 
genome editing has expanded, providing yet further potential options for the 
integrase LP system. In 2014, Yang et al used bioinformatic analysis of 
prophage genomes from conserved domain databases to identify 34 putative 
serine integrases and their attB and attP sites, 11 of which they used to 
successfully create memory switches in E. coli (Yang et al, 2014). Another 
novel serine integrase of potential use to genomic integrations of 
heterologous DNA that has been characterised in the last year is φJoe, a 
Streptomyces phage-derived integrase isolated by Fogg et al (2017) alongside 
its RDF, gp52. This adds to the list of integrase-RDF pairings available for use 
in synthetic biology and represents another addition to a possible multi-
integrase LP toolkit for synthetic biology.  
7.1.  Non-cognate activity of integrases and other RDFs 
Another primary objective of this work was to study the cross-compatibility of 
serine integrases and their non-cognate RDFs. In order to develop a multi-
integrase LP system, which includes reverse excision cassette exchanges 
between attL and attR sites formed following an initial LP cassette exchange, 
the fidelity of integrases and their RDFs must be explored. To use two 
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integrases in the same multi-LP cell in this reversible manner, there must be 
little cross-talk between an integrase and the RDF of the other integrase in 
the system. Here, φC31 integrase and TG1 integrase were investigated for 
that cross-reactivity. 
Through in vitro recombination assays, it was revealed that TG1 RDF gp25 was 
indeed capable of strongly activating φC31 attL-attR recombination, with a 
39% recombination of the substrate DNA observed (see Figure 5.2). This means 
that when establishing a multi-integrase LP system there will be caveats when 
using these two integrases and their RDFs (for secondary attL x attR cassette 
exchange) in the same system. On the other hand, φC31 RDF gp3 was shown 
to not significantly activate TG1 attL-attR recombination, with recombination 
of the substrate plasmid very close to the base level seen with only the TG1 
integrase without addition of any RDF (Figure 5.3). 
To support the prospect of a markerless landing pad system with very high 
cassette exchange efficiencies, the in vitro recombination assay data 
presented here acts to illustrate the strong unidirectionality of the serine 
integrases. This is particularly true of TG1 integrase, which showed only a 
very low level of 9% recombination of its attL and attR sites in the absence of 
RDF. However, when its RDF gp25 was added, attL-attR recombination 
increased dramatically to 72%. Once this attL-attR recombination has taken 
place, TG1 gp25 then shows very high inhibitory activity of the resulting attP 
and attB sites with decrease in attP-attB recombination from 77% without 
gp25 to 8% when the RDF is included, showing the powerful directionality of 
this integrase. As well as showing promise for the development of an efficient 
TG1 LP system, this result suggests that TG1 integrase as a prime candidate 
for development of other synthetic biology technologies due to its strict and 
responsive directionality control and high rates of recombination. 
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